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ions	across	 the	cell	membrane,	 thus	generating	electrical	 signals	 in	many	excitable	or	
unexcitable	 cells.	 Potassium	 channels	 play	 an	 important	 role	 in	 several	 biological	
functions:	their	contribution	is	important	in	determining	the	shape	and	the	duration	of	
the	 action	 potential,	 in	 the	 control	 of	 the	membrane	 potential,	 in	 the	modulation	 of	
hormone	secretion	and	epithelial	function.		
The	potassium	channel	family	can	be	classified	based	on	their	structure	in	channels	with	
two	 transmembrane	 segments	 (2TM),	 four	 transmembrane	 segments	 (4TM;	 2-pore	
domain),	 six	 transmembrane	 segments	 (6TM;	 voltage-gated	 K+	 channels	 and	 SK)	 or	
seven	transmembrane	segments	(7TM;	SLO,	Figure	1).		
The	 inward	 rectifier	 (Kir)	 family	 contains	 subunits	 with	 a	 topological	 structure	
characterized	by	two	TM	segments	flanking	the	pore-forming	domain;	they	assemble	as	
tetramers.	 They	are	 involved	 in	 the	 control	of	 several	biological	 functions	 in	different	
cell	types,	such	as	cardiac	myocytes	and	endothelial	cells.				
The	 two-pore	4TM	segments	K+	channels	 (K2P)	 family	assemble	as	dimers	and	play	an	
important	role	in	several	neuronal	functions.					
The	6TM	segments	(called	from	S1	to	S6)	K+	channels	family	includes	several	subfamilies	
called	 from	 Kv1.x	 to	 Kv12.x.	 Voltage-dependent	 K+	 channels	 contain	 a	 voltage-sensor	
domain	 (VSD;	 from	 S1	 to	 S4	 segments)	 with	 the	 S4	 segment	 containing	 positively-
charged	 amino	 acids	 that	 constitute	 the	 voltage-sensing	 elements.	 The	 small	



















as	 “big”	 K+	 channel	 (BK)	 or	maxi-K	 channels	 as	 these	 channels	 have	 an	 unusual	 large	












SLO1	 BK,	KCa,	Maxi-K,	KCa1.1	 KCNMA1	 10q22	
SLO2.1	 Slick,	KNa,	KCa4.2	 KCNT2	 1q31.3	

















protein	 with	 homology	 to	 voltage-dependent	 K+	 channels,	 but	 it	 has	 an	 extra	 TM	
segment	(S0),	allowing	the	N-terminus	to	face	the	extracellular	side	of	the	membrane.	In	
addition,	 these	 channels	 also	 contain	 hydrophobic	 domains	 at	 the	 C-terminus,	 called	




SLO2	 is	 the	 second	member	 of	 the	 SLO	 channels	 family	 that	 include	 two	 paralogues	
called	 KCNT1	 and	 KCNT2.	 Functional	 studies	 have	 revealed	 that	 KCNT1	 and	 KCNT2,	
similarly	to	BK	channels,	have	high	conductance	but,	differently	from	BK	are	potentiated	
by	 Na+	 (not	 Ca2+)	 ions,	 thereby	 underlying	 Na+-activated	 K+	 currents	 (IKNa).	 These	
currents	have	been	described	in	many	cells	[Hartung	et	al.,	1985],	including	guinea	pig	
cardiomyocytes	 [Kameyama	 et	 al.,	 1984]	 and	 a	 wide	 variety	 of	mammalian	 neurons,	
such	as	those	located	in	the	dorsal	root	ganglia	(DRG)	[Bischoff	et	al.,	1998].	
The	 identification	 of	 the	 Na+-activated	 K+	 currents	 has	 been	 achieved	 by	 means	 of	
different	 experimental	 tools;	 including	 the	 replacement	 of	 the	 external	 sodium	 by	
lithium	ions.	Lithium	is	a	much	weaker	activator	of	KNa	channels	than	sodium.	Because	
lithium	 promptly	 enters	 cells	 through	 voltage-dependent	 sodium	 channels,	 lithium	
replacement	 in	 voltage-clamp	 experiments	 reduces	 the	 net	 outward	 currents	 if	 KNa	
currents	are	present	[Hage	et	al.,	2012].	
The	 IKNa	 currents	are	believed	 to	play	an	 important	 role	under	 ischemic	 conditions	 in	
cardiomyocytes,	 due	 to	 a	 protective	 role	 prompted	 by	 the	 activation	 of	 large	 K+	
conductances	upon	dangerous	increase	in	[Na+]i	[Mitani	et	al.,	1992].	Similarly,	in	many	
neurons	 IKNa	 currents	 contribute	 to	 a	 long-lasting	 slow	 afterhyperpolarization	 (sAHP),	
which	 results	 from	 a	 slowly	 developing	 outward	 current	 evoked	 during	 sustained	
stimulation.	The	period	of	 reduced	excitability	afforded	by	sAHP	 is	 thought	 to	protect	
the	cell	from	repetitive	and	tetanic	activity.	It	has	been	shown	that,	whereas	the	early	
part	of	sAHP	is	dependent	on	Ca2+	influx	during	stimulation,	the	late	part	of	sHAP	is	Na+	
sensitive	 [Schwindt	 et	 al.,	 1998a,b].	 Similar	 Na+-dependent	 sHAP	 has	 also	 been	



















gated	 K+	 channels	 in	 having	 a	 symmetrical	 arrangement	 of	 membrane-spanning	
segments	clustered	around	a	water-filled,	K+	ion-selective	pore.  
The	a-subunit	of	SLO2	channels	has	six	hydrophobic	 transmembrane	segments	 (S1-S6)	
along	 with	 a	 pore-lining	 loop	 that	 is	 found	 between	 the	 S5-S6	 segments.	 The	 SLO2	
channels	 also	 exhibit	 a	 large	 C-terminal	 region	 (over	 900	 amino	 acids	 in	 length)	 that	
greatly	 exceeds	 the	 length	 of	 the	 region	 encompassing	 the	 membrane-spanning	
domains	 and	 contains	 both	 hydrophobic	 and	 hydrophilic	 domains.	 Both	 SLO2.1	 and	
SLO2.2	 channels	 lack	 the	 canonical	 gating	 charges	 in	 the	 S4	 membrane-spanning	
segment	usually	associated	with	voltage	sensing	and	both	exhibit	a	low	intrinsic	voltage	
dependence	of	activation	[Yuan	et	al.,	2003].	The	N-	and	C-terminus	of	SLO2	channels	
are	 located	 on	 the	 intracellular	 side.	 The	 C-terminus	 of	 SLO2	 subunits	 contains	 two	
predicted	 regulators	 of	 K+	 conductance	 (RCK)	 domains	 that	 stack	 on	 the	 top	 of	 each	
other	 and	 form	 a	 gating	 ring	 underneath	 the	 channel	 pore	 (Figure	 3).	 X-ray	





Figure	 3	 Topological	 structure	 of	 SLO2	 a-subunit.	 SLO2	 channels	 have	 six	 transmembrane	 domains.	 The	
transmembrane	domains	are	labeled	as	S1-S6,	with	the	P-loop	located	between	the	S5-S6	segments.	Both	the	N-	and	






by	 using	 Cryo-Electron	 Microscopy,	 MacKinnon	 and	 coll.	 (2017)	 solved	 the	 crystal	
structure	of	KCNT1	channels	in	the	open	configuration	and	revealed	structural	features	
that	were	not	present	 in	 the	closed	configuration	of	KCNT1	channels.	 In	particular,	 in	
the	open	configuration,	the	gating	ring	is	firmly	compressed	against	the	transmembrane	
domain.	 In	 addition,	 a	 subdomain	 structure	 of	 the	 membrane-facing	 surface	 of	 the	
gating	 ring	 (RCK1	N-lobe)	 showed	 an	 expanded	 conformation	 induced	 by	Na+	 ions,	 if	
compared	 to	 the	 closed	 configuration.	 This	 structure	 is	 also	 responsible	 for	 pore	
opening,	by	causing	the	displacement	of	the	S6	helices	radially	away	from	the	pore	axis	
[Hite	et	al.,	2017].	By	contrast,	in	the	closed	and	Na+-unbound	state,	the	S6	helices	were	





Figure	4	Architecture	of	 closed	and	open	KCNT1	 channel	 subunits	by	 cryo-electron	microscopy.	 (A,	B)	Cryo	EM	







part	 of	 the	 pore	 domain	 and	 the	 S6	 domain	 is	 similar	 to	 that	 of	 SLO1	 (BK)	 large	
conductance	calcium-activated	K+	channels	[Dryer,	1994].	
KCNT1	 channel	 was	 first	 cloned	 and	 expressed	 in	 1998	 [Joiner	 et	 al.,	 1998]	 and	was	
found	 to	 be	 regulated	 by	 intracellular	 Na+	 ions	 in	 2003	 [Yuan	 et	 al.,	 2003].	 KCNT1	
channels	elicit	outwardly	rectifying	K+	currents	that	increase	upon	depolarization.	These	
currents	 show	 complex	 activation	 kinetics,	 with	 an	 instantaneous	 time-independent	
component,	followed	by	a	slower,	time-dependent	one.		
When	 expressed	 either	 in	mammalian	 cell	 lines	 or	 Xenopus	 oocytes	 KCNT1	 channels	





overpassing	 physiological	 Na+	 levels	 but	 possibly	 occurring	 during	 high	 frequency	
neuronal	 activity	or	upon	hypoxic	 insults.	 These	observations	 suggest	 that	 the	 role	of	
KNa	channels	may	be	strictly	limited	to	these	physiopathological	conditions.	However,	it	
has	 to	 be	 highlighted	 that	 another	 activator	 of	 KCNT1	 current	 is	 the	 nicotinamide	
adenine	 dinucleotide	 (NAD+)	 [Tamsett	 et	 al.,	 2009],	 which	 induces	 a	 significant	
reduction	 in	 the	 [Na+]i	 required	 for	current	activation	and	 likely	allows	KCNT1	current	
activation	also	in	physiological	conditions.	These	observations	are	supported	by	the	fact	
that	both	Na+	and	NAD+	binding	sites	are	localized	in	the	RCK2	domain.	In	particular,	the	







In	 fact,	 five	 different	 transcripts	 from	 the	 rat	 KCNT1	 gene	 have	 been	 described,	 and	
these	are	predicted	to	produce	KCNT1	channels	that	differ	 in	their	cytoplasmic	amino	
termini.	 In	particular,	 the	N-terminal	domain	of	Slack-A	 is	 smaller	 than	that	of	Slack-B	
and	the	sequence	of	Slack-A	N-terminal	domain	very	closely	resembles	the	N-terminus	
of	the	KCNT2	subunits.	




of	 one	 or	 the	 other	 of	 these	 two	 isoforms	 is	 likely	 to	 shape	 the	 specific	 pattern	 of	
response	 to	 repetitive	 stimulation,	 as	 observed	 in	 simulations	 performed	 in	 neuronal	








KCNT2	 channels	 have	 a	 conductance	 that	 is	 intermediate	 between	 that	 of	 SLO1	 (BK)	
calcium-activated	K+	channels	and	other	K+	channels.			
Overall,	 the	 sequence	 of	 KCNT2	 channel	 is	 74%	 identical	 to	 that	 of	 KCNT1;	 the	
transmembrane	 domains	 and	 the	 RCK	 domains	 are	 almost	 identical.	 The	 greatest	
divergence	between	KCNT1	and	KCNT2	channels	occurs	at	the	distal	C-terminal	regions.	
The	predicted	cytoplasmic	N-terminus	of	KCNT2	is	similar	to	that	of	the	Slack-A	isoform.		
Also	 the	 electrophysiological	 properties	 of	 KCNT2	 currents,	 recorded	 in	 mammalian	
cells	 or	Xenopus	 oocytes,	 resemble	 those	of	 Slack-A:	 in	 fact,	 KCNT2	 channels	 activate	
very	rapidly	upon	depolarization	and	have	multiple	subconductance	states.	Also,	KCNT2	
currents	are	activated	by	Na+	ions	in	a	concentration-dependent	and	reversible	manner.	
Concentration-response	 curves	 for	 activation	 of	 KCNT2	 channels	 revealed	 that	 the	
effective	Na+	 concentrations	 for	50%	 (EC50)	of	KCNT2	channels	activation	 is	89	mM,	a	
value	 even	 greater	 than	 that	 described	 for	 KCNT1	 channels	 activation	 (40	 mM).	 By	
contrast,	whereas	KCNT1	channels	activation	has	an	absolute	requirement	of	Na+	ions,	
KCNT2	 channels	 have	 a	 basal	 level	 of	 activity	 even	 in	 the	 absence	 of	 Na+	 ions	
[Bhattacharjee	et	al.,	2003].	
In	 addition	 to	 their	 Na+-sensitivity,	 both	 KCNT1	 and	 KCNT2	 channel	 subunits	 can	 be	
activated	by	intracellular	chloride	ions	(Cl-)	[Yuan	et	al.,	2000],	although	there	is	a	large	
difference	 in	 their	 sensitivity:	 in	 fact,	 there	 is	 an	 approximately	 five-fold	 increase	 in	







Na+-activated	 (KNa)	 and	 ATP-sensitive	 (KATP)	 K	 +	 channels.	 Indeed,	 KCNT2	 channel	
subunits	 also	 contain	 a	 regulatory	 nucleotide-binding	 site	 that	 is	 responsible	 for	ATP-
mediated	 inhibition	of	 channel	 activity,	 thus	 suggesting	 a	more	 specialized	protective	
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role	under	 ischemic	 conditions	 and	 seizure	 activity	 in	neuronal	 cells.	 The	ATP-binding	
site	 is	 located	 in	the	second	RCK	domain,	making	the	channel	sensitive	to	cytoplasmic	








their	 properties	 from	 those	 of	 homomeric	 channels	 [Chen	 et	 al.,	 2009].	 The	 unitary	
conductance	 of	 Slack/Slick	 heteromeric	 channels	 results	 to	 be	 intermediate	 between	
that	 of	 Slack	 (~	 180	 pS)	 and	 Slick	 (~	 140	 pS)	 homomers.	 Moreover,	 assembly	 of	
heteromeric	Slack/Slick	channels	appears	to	be	specific	for	the	Slack-B	isoform:	in	fact,	
when	 Slick	 and	 Slack-B	 are	 coexpressed	 at	 1:1	 ratio,	 either	 in	 Xenopus	 oocytes	 or	 in	
mammalian	HEK293	cells,	a	18-25	fold	increase	in	current	amplitude	is	observed	when	
compared	 to	 the	 currents	 expressed	by	 either	 subunit	 alone	 [Chen	et	 al.,	 2009].	 This	
functional	effect	is	due	to	an	increased	protein	expression	at	the	plasma	membrane	(as	
demonstrated	 in	 biotinylation	 experiments).	 These	 results	 were	 obtained	 by	 using	
chimeric	 channels	 that	 replaced	 the	 cytoplasmatic	 N-terminal	 domain	 of	 KCNT2	with	
that	 of	 Slack-B.	 The	 coexpression	 of	 this	 modified	 Slick	 channel	 with	 wild-type	 Slick	
channels	 in	 oocytes	 produced	 a	 30-fold	 increase	 in	 whole-oocyte	 currents,	 which	 is	
similar	to	the	increase	obtained	when	Slack-B	subunits	were	co-expressed	with	Slick.	
Interaction	 between	 Slack-B	 and	 Slick	 subunits	 was	 also	 demonstrated	 by	 co-

















and	 this	 effect	 seems	 to	 be	 mediated	 by	 modification	 within	 the	 C-terminus	 of	 the	
channels	[Santi	et	al.,	2006].	
Heteromeric	Slack-B/Slick	channels	also	 respond	to	PKC	activation	 in	a	manner	 that	 is	
distinct	 from	 that	 of	 either	 subunit	 expressed	 alone:	 in	 fact,	 application	 of	 PKC	





KCNT1	 and	 KCNT2	 channel	 have	 been	 coexpressed	 in	 Xenopus	 oocytes	 with	 the	M1	
muscarinic	receptor	and	the	mGluR1	metabotropic	receptor	[Santi	et	al.,	2006].	These	
are	Gaq	protein-coupled	receptors	that	lead	to	the	activation	of	PKC.	The	activation	of	
these	 receptors	 leads	 to	 an	 increase	 in	 KCNT1	 currents	 and	 a	 reduction	 of	 KCNT2	
currents,	 consistent	 with	 the	 above	 mentioned	 effects	 prompted	 by	 a	 direct	 PKC	




(DA)	 and	 octopamine	 (OA),	 in	 an	 opposite	 way	 in	 Kenyon	 cells	 isolated	 from	 the	
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mushroom	body	of	the	cricket	Gryllus	bimaculatus.	
In	particular,	 in	 these	cells	OA	and	DA	respectively	 increased	and	decreased	 the	open	
probability	of	SLO2	channels.	In	addition,	Na+-activated	K+	channels	are	also	modulated	
by	 cAMP/PKA	 (protein	 kinase	 A)	 signaling	 pathways	 leading	 to	 an	 increased	 channel	






(GPCR)	 and	 are	 classified	 into	 four	 subtypes:	 the	D1-like	 dopamine	 receptors	 (Dop1),	
invertebrate	dopamine	 receptors	 (INDRs,	 also	 known	as	Dop2),	 the	D2-like	dopamine	
receptors	 (Dop3)	 and	 the	 dopamine/ecdysteroid	 receptors	 (DopEcR).	Once	 dopamine	
receptors	are	activated	by	dopamine,	downstream	signaling	systems,	such	as	the	cyclic	

















• Interactions	 of	 KCNT1	 channels	with	 the	 Fragile	 X	Mental	 Retardation	 Protein	
(FMRP)	
The	Fragile	X	syndrome	is	the	most	common	inherited	form	of	 intellectual	disability	 in	
humans.	 This	 syndrome	 is	 caused	 by	 a	 loss	 of	 expression	 of	 the	 RNA-binding	 protein	
FMRP	 (Fragile	 X	mental	 retardation),	 also	 required	 for	 the	 normal	 activity-dependent	
protein	 translation	 in	neurons.	 The	cytoplasmic	C-terminal	domain	of	KCNT1	 subunits	
interacts	with	 FMRP	 that	 acts	 as	 a	 potent	 activator	 of	 KCNT1	 channels.	 This	 protein-
protein	 interaction	 is	 associated	 with	 the	 almost	 complete	 elimination	 of	
subconductance	states.	Furthermore,	 the	application	of	a	 recombinant	FMRP	 (1-298),	
which	contains	only	the	interaction	domains	of	FMRP	with	KCNT1,	reversibly	increases	





1.7	 Distribution	 of	 KCNT1	 and	 KCNT2	 channel	 subunits	 in	 the	 Central	
Nervous	System	(CNS)		
 
Cloning	of	 KCNT1	 and	KCNT2	 genes	 and	 the	development	of	 specific	 antibodies	 have	
provided	 the	 unique	 opportunity	 to	 carry	 out	 a	 detailed	 study	 of	 the	 regional	
distribution	of	the	encoded	subunits.	The	highest	levels	of	KCNT1	and	KCNT2	channels	
have	 been	 found	 in	 the	 brain,	 with	 lower	 expression	 levels	 in	 the	 heart	 and	 kidney	
[Joiner	 at.,	 1998;	 Yuan	 et	 al.,	 2003;	 Bhattachaerjee	 and	 Kaczmarek,	 2005].	 KCNT2	 is	
highly	 expressed	 in	 neurons,	 whereas	 no	 staining	 is	 found	 in	 glial	 cells.	 Strong	
hybridization	 was	 found	 throughout	 the	 brain,	 including	 the	 cerebral	 cortex,	
hippocampus,	 deep	 cerebellar	 nuclei,	 cerebellar	 Purkinje	 cells,	 reticular	 tegmental	
nucleus	of	the	pons,	preoptic	nucleus,	substantia	nigra,	and	auditory	brainstem	nuclei	
[Joiner	et	al.,	1998].	
More	 recently,	 distribution	 pattern	 in	 the	mouse	 brain	 of	 KCNT1	 and	 KCNT2	 channel	
subunits	 has	 been	 also	 described	 in	 more	 detail.	 The	 two	 channels	 exhibit	 distinct	
distribution,	but	their	expression	overlaps	in	some	regions,	including	the	olfactory	bulb,	
subfornical	 organ,	 substantia	 nigra,	 pars	 compacta,	 oculomotor	 and	 red	 nuclei,	
interpeduncular	and	rhabdoid	nuclei,	nucleus	of	the	trapezoid	body,	reticulotegmental	
nucleous	of	pons,	and	the	inferior	olivary	complex.	Several	brain	structures	also	exhibit	
expression	 pattern	 in	 which	 KCNT1	 and	 KCNT2	 do	 not	 overlap.	 In	 particular,	 KCNT1	
immunoreactivity	 was	 found	 alone	 in	 islands	 of	 Calleja,	 nuclei	 of	 the	 extended	
amygdala,	hippocampal	formation,	and	ventromedial	hypothalamic	and	arcuate	nuclei.	
In	 contrast,	 a	 marked	 KCNT2	 channel	 immunolabeling	 was	 found	 in	 globus	 pallidus,	







Potassium	 (K+)	 channels	 underlie	 outward	 K+	 currents	 that	 contribute	 to	 membrane	
repolarization	 and	 hyperpolarization,	 thus	 limiting	 the	 neuronal	 excitability.	 Such	
channels	are	 the	only	 ion-selective	cation	channels	 that	have	an	equilibrium	potential	
near	the	typical	cellular	resting	potential.		
Potassium	 channels	 are	 expressed	 in	 almost	 every	 cell,	 particularly	 in	 neurons	 and	
excitable	tissues,	where	they	regulate	the	shape	and	duration	of	action	potentials,	the	
firing	 rate	 and	 the	 overall	 excitability	 of	 cells.	 The	 functional	 heterogeneity	 of	 K+	
currents	 expressed	 in	 excitable	 and	 non-excitable	 cells	 is	 primarily	 due	 to	 the	 large	
number	 of	 genes	 either	 encoding	 pore-forming	 (a)	 or	 accessory	 (b)	 subunits	 in	 the	
mammalian	genome.	Additional	 factors,	 such	as	 alternative	 splicing,	RNA	editing,	 and	
ability	 to	 form	 homomeric	 or	 heteromeric	 complexes	 among	 pore-forming	 and	
accessory	 subunits	 also	 contribute	 to	 the	 K+	 channel	 properties	 diversification	 and	





Epilepsies	 are	 common	 neurological	 disorders	 in	 infancy,	 childhood	 and	 adolescence	
characterized	 predominantly	 by	 recurrent	 and	 unpredictable	 interruptions	 of	 normal	
brain	function,	called	epileptic	seizures	(Fisher	et	al.,	2005).	
According	to	the	International	League	Against	Epilepsy	(ILAE),	an	epileptic	seizure	is	“a	
transient	 occurrence	 of	 signs	 and/or	 symptoms	 due	 to	 abnormal	 excessive	 or	
synchronous	neuronal	activity	in	the	brain”.	
The	definition	of	epilepsy	also	 implies	the	occurrence	of	at	 least	one	epileptic	seizure,	
where	 the	 term	 “seizure”	 indicates	 an	 “abnormal	 and	 synchronous	 excitation	 of	 a	
neuronal	population	lasting	seconds	or	minutes”.		
Epileptic	 seizures	 arise	 when	 functional	 alterations	 of	 neurons	 occur,	 causing	 an	





physiological	 balance	 between	 neuronal	 excitation	 and	 inhibition.	 Cell	 membrane	 of	
neurons	have	several	different	ion	channels,	including	Na+	and	K+	leak	channels	as	well	
as	 voltage-gated	Na+	 and	 K+	 channels	 that	 allow	 the	 passage	 of	 ions	 as	 a	 function	 of	
their	electrochemical	gradients.	Cl-	and	Na+	are	mainly	located	in	the	extracellular	fluid,	
while	 K+	 ions	 and	 negatively	 charged	 proteins	 are	 located	 in	 the	 intracellular	 fluid	
therefore	K+	ions	leak	out	of	the	cell,	moving	down	their	concentration	gradient.	As	K+	




the	 cell.	 At	 some	 point	 in	 this	 process,	 the	 electrical	 force	 attracting	 K+	 into	 the	 cell	
becomes	equal	 in	magnitude	 to	 the	chemical	concentration	gradient	driving	K+	out	of	
the	cell.	At	that	point,	called	equilibrium	potential	for	K+	(-90	mV),	net	movement	of	K+	
across	the	membrane	stops.	By	contrast,	because	Na+	is	more	concentrated	outside	the	




Therefore	 it	 is	 plausible	 that	 abnormalities	 in	 Na+	 or	 K+	 channel	 function	 can	
dramatically	 alter	 neuronal	 firing,	 through	 different	 mechanism	 depending	 on	 the	
possibility	 that	 specific	 classes	 of	 ion	 channels	 are	 expressed	 in	 inhibitory	 and/or	
excitatory	neurons.		
The	 concept	 that	 an	 alteration	 of	 the	 balance	 between	 excitation	 and	 inhibition	
processes	 is	 responsible	 for	 the	 onset	 of	 epileptic	 seizures	 has	 led	 to	 the	 design	 of	
anticonvulsant	 drugs	 able	 to	 restore	 the	 physiological	 neuronal	 excitability.	 The	
traditional	antiepileptic	drugs,	 in	fact,	act	mainly	through	 inhibition	of	Na+	(phenytoin,	
carbamazepine,	 lamotrigine)	 or	 Ca2+	 (ethosuximide)	 channels	 or	 by	 increasing	 the	
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inhibitory	 GABAergic	 transmission	 (phenobarbital,	 benzodiazepines,	 tiagabine,	
vigabatrin).	
The	 etiology	 of	 epilepsy	 is	 very	 heterogeneous:	 many	 different	 genetic	 and	
pathophysiological	 factors,	 alone	or	 in	 combination,	 can	underlie	 an	 increased	 risk	 of	
developing	a	seizure	disorder	[Berg	et	al.,	2010].	
The	 contribution	 of	 genetic	 factors	 is	 observed	 when	 the	 epileptic	 seizures	 are	 the	
direct	 result	 of	 a	 known	 or	 presumed	 genetic	 defect.	 Also,	 genetic	 causes	 can	 be	
heterogeneous:	 in	 fact,	 epilepsy-causing	 mutations	 have	 been	 identified	 in	 different	
genes;	in	addition,	these	mutations	can	be	inherited,	can	occur	de	novo	in	the	affected	
individuals,	or	in	rare	case	can	consist	in	chromosomal	abnormalities	(e.g.,	trisomy	21).	
The	 assignment	 of	 the	 disorder	 as	 genetic	 does	 not	 exclude	 the	 possibility	 that	
environmental	factors	may	contribute	to	the	expression	of	disease.	










One	 third	 of	 the	 epilepsies	 is	 refractory	 to	 medical	 treatments,	 and	 an	 important	
fraction	of	them	have	a	significant	detrimental	effect	on	cognitive	and	brain	functions.	
These	 conditions	 in	 which	 the	 epileptic	 activity	 during	 brain	 maturation	 is	 the	 main	
causative	 factor	 of	 severe	 cognitive	 and	 behavioral	 impairments,	 are	 referred	 to	 as	
epileptic	encephalopathies	 (EEs),	a	group	of	devastating	epileptic	disorders	 that	occur	
early	 in	 life	 and	 are	 often	 characterized	 by	 drug	 resistance,	 persistent	 severe	
electroencephalographic	 abnormalities,	 cognitive	 dysfunction	 or	 decline	 with	 poor	
developmental	outcome	[Scheffer	et	al.,	2017].	The	etiologies	of	an	encephalopathy	are	
heterogeneous	 and	 the	 brain	 dysfunction	 can	 occur	 either	 acutely	 or	 chronically	 and	
can	 be	 static	 or	 degenerative	 [Helbig	 et	 al.,	 2017].	 Refractory	 seizures,	 severe	 EEG	
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dominant	 epilepsies.	 These	 findings,	 including	 the	 discoveries	 of	 CHRNA4,	 SCN1A,	








advent	 of	 large-scale	 next	 generation	 sequencing	 technologies	 has	 strongly	 increased	
the	speed	of	gene	discovery,	 leading	 to	 the	 identification	of	a	growing	number	of	 ion	
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and	 non-ion-channels	 genes	 in	 sporadic	 severe	 and	 treatment-resistant	 epileptic	
encephalopathies	 (Table	 2).	 An	 important	 contribution	 to	 the	 identification	 of	 novel	
genes	 responsible	 for	 Epileptic	 Encephalopathies	 has	 been	 given	 by	 new	 genetic	
technologies	 for	 mutation	 detection	 in	 human	 genome,	 such	 as	 Next-Generation	
Sequencing	(NGS)	and/or	Whole	Exome	Sequencing	(WES)	[Choi	et	al.,	2009].	The	NGS	
technology,	 also	 known	 as	 “massive	 parallel	 sequencing”,	 has	 largely	 replaced	
traditional	 Sanger	 sequencing	 in	 the	 research	 and	 clinical	 laboratories	 allowing	 the	
simultaneous	sequencing	of	millions	of	short	fragments	of	DNA.	The	NGS	technology	is	
rapidly	 becoming	 a	 fundamental	 tool	 for	 genetic	 and	 functional	 genomics,	 since	 this	
technique	allows	the	sequencing	of	entire	gene	panels,	 ranging	 from	a	 few	to	several	
hundred	 genes.	 In	 addition,	 advances	 in	 genome	 technologies	 have	 allowed	WES,	 in	
which	the	exon	sequence	of	nearly	all	~	2000	human	genes	are	sequenced	in	order	to	
identify	 genetic	 mutations	 [Mefford,	 2015].	 Each	 of	 these	 approaches	 has	 been	
fundamental	 for	 the	 discovery	 that	 about	 75%	 of	 patients	 with	 epileptic	
















EIEE1	 ARX	 XL	 Homeobox	protein	ARX	
EIEE2	 CDKL5	 XL	 Cyclin-dependent	kinase-like	5	
EIEE3	 SLC25A22	 AR	 Mitochondrial	glutamate	carrier	1	
EIEE4	 STXBP1	 AD	 Syntaxin-binding	protein	1	
EIEE5	 SPTAN1	 AD	 Spectrin	alpha	chain,	non-erythrocytic	1	
EIEE6	 SCN1A	 AD	 Sodium	channel	protein	type	1	subunit	alpha	
EIEE7	 KCNQ2	 AD	 Potassium	voltage-gated	channel	subfamily	KQT	member	2	
EIEE8	 ARHGEF9	 XL	 Rho	guanine	nucleotide	exchange	factor	9	
EIEE9	 PCDH19	 XL	 Protocadherin-19	
EIEE10	 PNKP	 AR	 Bifunctional	polynucleotide	phosphatase/kinase	
EIEE11	 SCN2A	 AD	 Sodium	channel	protein	type	2	subunit	alpha	
EIEE12	 PLCB1	 AR	 1-phosphatidylinositol	4,5-bisphosphate	phosphodiesterase	
β-1	
EIEE13	 SCN8A	 AD	 Sodium	channel	protein	type	8	subunit	alpha	
EIEE14	 KCNT1	 AD	 Potassium	channel	subfamily	T	member	1	
EIEE15	 ST3GAL3	 AR	 CMP-N-acetylneuraminate-β-1,4-galactoside	a-2,3-
sialyltransferase	
EIEE16	 TBC1D24	 AR	 TBC1	domain	family	member	24	
EIEE17	 GNAO1	 AD	 Guanine	nucleotide-binding	protein	G(o)	subunit	alpha	
EIEE18	 SZT2	 AR	 Protein	SZT2	
EIEE19	 GABRA1	 AD	 Gamma-aminobutyric	acid	receptor	subunit	alpha-1	
EIEE20	 PIGA	 XL	 Phosphatidylinositol	N-acetylglucosaminyltransferase	
subunit	A	
EIEE21	 NECAP1	 AR	 Adaptin	ear-binding	coat-associated	protein	1	
EIEE22	 SLC35A2	 XL	 UDP-galactose	translocator	
EIEE23	 DOCK7	 AR	 Dedicator	of	cytokinesis	protein	7	
EIEE24	 HCN1	 AD	 Potassium/sodium	hyperpolarization-activated	cyclic	
nucleotide-gated	channel	1	
EIEE25	 SLC13A5	 AR	 Solute	carrier	family	13	member	5	
EIEE26	 KCNB1	 AD	 Potassium	voltage-gated	channel	subfamily	B	member	1	
EIEE27	 GRIN2B	 AD	 Glutamate	receptor	ionotropic,	NMDA	2B	
EIEE28	 WWOX	 AR	 WW	domain-containing	oxidoreductase	
EIEE29	 AARS	 AR	 Alanine--tRNA	ligase	
EIEE30	 SIK1	 AD	 Serine/threonine-protein	kinase	SIK1	
EIEE31	 DNM1	 AD	 Dynamin-1	
EIEE32	 KCNA2	 AD	 Potassium	voltage-gated	channel	subfamily	A	member	2	
EIEE33	 EEF1A2	 AD	 Elongation	factor	1-alpha	2	
EIEE34	 SLC12A5	 AR	 Solute	carrier	family	12	member	5	





2.3	 KCNT1	 mutations	 result	 in	 a	 wide	 range	 of	 seizure	 disorders	 and	
Intellectual	Disabilities	
	
Mutations	 in	 KCNT1	 gene	 have	 been	 identified	 in	widely-diverging	 clinical	 conditions,	
ranging	 from	 very	 severe	 form	 of	 epilepsy	 (MMPSI)	 to	 milder	 epileptic	 diseases	
(ADNFLE)	[Lim	et	al.,	2016].	In	vitro	functional	studies	revealed	that	all	KCNT1	mutations	
are	able	to	induce	an	increase	in	current	density	when	compared	to	wild-type	channels,	
a	 result	 referred	 to	 as	 gain-of-function	 effect.	 In	 contrast,	 only	 one	 single	 study	 has	
reported	a	KCNT1	mutation	causing	a	reduction	in	channel	activity,	also	referred	to	as	
loss-of-function	effect	[Evely	et	al.,	2017].	





The	 syndrome	 of	 Malignant	 Migrating	 Partial	 Seizures	 of	 Infancy	 (MMPSI)	 or	 EIEE14	
(Early	 Infantile	 Epileptic	 Encephalopathy	 14)	 is	 a	 severe	 form	 of	 epilepsy	 that	 begins	
very	early	 in	 life.	Recurrent	seizures	begin	before	the	age	of	6	months,	but	commonly	
start	within	a	few	weeks	after	birth.	Although	affected	patients	may	develop	normally	at	
first,	 progression	 stalls	 and	 skills	 decline	 when	 seizures	 begin;	 as	 a	 result,	 affected	
individuals	have	profound	developmental	delay.	The	seizures	in	MMPSI	are	described	as	
partial	 (or	 focal)	because	seizure	activity	occurs	 in	 specific	 regions	of	 the	brain	 rather	
than	affecting	the	entire	brain.	Seizure	activity	may	appear	in	multiple	locations	of	the	
brain	 or	 move,	 hence	 the	 definition	 of	 migrating	 seizures,	 from	 one	 brain	 region	 to	
another	during	an	episode	(Figure	6).	
Migrating	focal	motor	seizures	at	onset,	nearly	continuous	multifocal	seizures	migrating	
between	 cortical	 regions	 and	 hemispheres,	 resistance	 to	 antiepileptic	 drugs,	 lack	 of	
demonstrable	 etiology,	 and	 severe	 psychomotor	 delay	 on	 follow-up	 are	 typical	 in	
MMPSI	patients	[Coppola	et	al.,	1995].	
The	natural	history	of	this	syndrome	allows	recognition	of	three	distinct	phases.		A	first	






seizures	 sometimes	 occur	 at	 the	 onset	 of	 the	 second	 phase.	 Interictal	





about	 1–12	 months,	 focal	 polymorphous	 seizures	 shortly	 become	 very	 frequent,	
occurring	in	clusters	of	5–30	several	times	a	day	or	being	almost	continuous	for	several	
days.	With	 increasing	age,	 the	amplitude	of	 the	 ictal	discharge	 tends	 to	 increase,	and	
frontal	areas	are	more	frequently	affected	[Dulac,	2005].	The	age	at	onset	of	the	third	
phase	may	vary	highly,	ranging	from	the	end	of	the	first	year	to	5	years	of	age	and	over.	
This	 phase	 is	 a	 relatively	 seizure-free	 period,	 although	 spontaneous	 intercurrent	
illnesses	would	easily	trigger	clusters	of	seizures	or	occasional	status	epilepticus.	
Computed	 tomography	 (CT)	 and	 magnetic	 resonance	 imaging	 (MRI)	 are	 generally	
normal	 at	 the	 beginning	 of	 the	 illness.	 During	 follow-up,	 there	 may	 be	 a	 mild	 to	
moderate	enlargement	of	both	subarachnoid	and	ventricular	spaces.	
Overall,	the	long-term	outcome	of	migrating	focal	seizures	in	infancy,	with	reference	to	
seizures	 and	psychomotor	 development,	 remains	 very	 severe.	 Even	when	 it	 becomes	
possible	 to	 shorten	 the	 duration	 of	 migrating	 status	 epilepticus	 and/or	 increase	 the	
intervals	 between	 active	 phases	 with	 different	 combination	 therapies,	 psychomotor	
abilities	are	poor,	inevitably	evolving	into	mental	retardation.	Not	surprisingly,	absence	
of	language	and	hypotonia	are	also	commonly	noted	in	MMPSI	patients	[McTague	et	al.,	
2013].	 Because	 of	 the	 serious	 health	 problems	 caused	 by	 MMPSI,	 many	 affected	
individuals	do	not	survive	past	infancy	or	early	childhood.	
Possible	causes	for	seizure	development	in	MMPSI	patients	has	remained	elusive	until	
recently.	 Neurometabolic,	 blood	 gas	 and	 serum	 tests	 are	 typically	 normal,	 and	 brain	
lesions	 are	 rarely	 observed	 in	 affected	 patients	 [Nabbout	 and	 Dulac,	 2008].	 Genetic	
etiologies	for	MMPSI	were	first	identified	in	2011,	with	the	discovery	of	SCN1A	(Nav	1.1)	
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Ohtahara	 syndrome	 (OS)	 was	 originally	 described	 as	 an	 early	 infantile	 epileptic	
encephalopathy	 with	 suppression	 bursts	 [Ohtahara	 et	 al.,	 1976].	 OS	 is	 one	 of	 the	
earliest	 seizures	 in	 its	 presentation.	 Infants	 acutely	 develop	 tonic	 spasms	 that	 can	be	
either	 generalized	 or	 lateralized,	 can	 occur	 both	 singly	 or	 in	 clusters,	 and	 are	
independent	of	the	sleep	cycle.	A	majority	of	OS	patients	show	severe	developmental	




etiologies	have	also	been	 identified	 in	a	 subset	of	OS	patients.	To	date,	alterations	 in	
five	genes	have	been	 found	 in	OS	patients:	 ion	channels	KCNQ2	 (Kv7.2)	 [Saitsu	et	al.,	
2012a],	SCN2A	(Nav1.2)	[Nakamura	et	al.,	2013],	KCNT1	(Slack)	[Martin	et	al.,	2014];	the	
transcription	factors	ARX	and	the	synaptic	binding	protein	STXBP1.	Approximately	one	
third	of	patients	with	Ohtahara	 syndrome	will	 also	develop	other	 seizure	 types,	most	






Similar	 to	OS,	 the	 pathogenesis	 of	 early	myoclonic	 encephalopathy	 (EME)	 is	 variable,	
with	 structural,	metabolic,	 and	 genetic	 abnormalities	 all	 playing	 a	 role. Many	 seizure	
types	 may	 occur,	 but	 myoclonic	 seizures	 (very	 frequent,	 brief,	 single	 or	 repetitive,	
erratic,	 and	 nearly	 continuous	 body	 jerks)	 characterize	 this	 epilepsy	 syndrome	 and	
differentiate	 it	 from	OS.	 	 Some	may	also	have	 focal	motor	 seizures,	 tonic	 seizures,	or	
rarely	 tonic	 spasms,	 which	 appear	 later.	 ErbB4	 is	 one	 gene	 example	 associated	 with	















Autosomal	 dominant	 nocturnal	 frontal	 lobe	 epilepsy	 (ADNFLE)	 is	 characterized	 by	
clusters	of	nocturnal	motor	seizures,	which	are	often	stereotyped	and	brief	(5	seconds	
to	 5	minutes).	 They	 vary	 from	 simple	 arousals	 from	 sleep	 to	 dramatic,	 often	 bizarre,	
hyperkinetic	events	with	tonic	or	dystonic	features.	Affected	individuals	may	experience	
aura.	 Retained	 awareness	 during	 seizures	 is	 common.	 A	 minority	 of	 individuals	
experience	 daytime	 seizures.	 Onset	 ranges	 from	 infancy	 to	 adulthood.	 About	 80%	 of	
individuals	develop	ADNFLE	 in	 the	 first	 two	decades	of	 life;	mean	age	of	onset	 is	 ten	
years.	Clinical	neurologic	examination	 is	normal	and	 intellect	 is	usually	preserved,	but	




less	 frequent. Molecular	 genetic	 testing	 reveals	 pathogenic	 variants	 in	 CHRNA4,	
CHRNB2,	CHRNA2,	KCNT1,	DEPDC5,	or	CRH	in	approximately	20%	of	individuals	with	a	






Given	their	 role	 in	 the	regulation	of	neuronal	excitability	and	their	 involvement	 in	 the	
pathogenetic	 mechanisms	 of	 several	 epileptic	 disorders,	 these	 sodium-activated	
potassium	channels	are	important	pharmacological	targets.		
The	pharmacological	properties	of	KCNT1	and	KCNT2	channels	are	similar	to	each	other,	
but	 differ	 from	 those	 of	 many	 other	 potassium	 channels.	 In	 fact,	 KCNT1	 and	 KCNT2	
channels	 are	 only	 weakly	 sensitive	 to	 the	 aspecific	 potassium	 channel	 blocker	
tetraethylammonium	(TEA):	 in	particular,	1	mM	TEA	had	little	effect	on	both	channels	





inhibit	 KCNT1	 and	 KCNT2	 channels	 in	 cardiac	 cells	 [Mori	 et	 al.,	 1996;	 Li	 et	 al.,	 1999].	
Some	 of	 these	 compounds,	 such	 as	 clofilium,	 bepridil,	 and	 quinidine	 (Figure	 7),	 have	
been	 also	 found	 to	 be	 very	 effective	 and	 reversible	 blockers	 of	 KCNT1	 and	 KCNT2	
currents	 expressed	 in	 oocytes	 and	mammalian	 cells. Clofilium	 inhibits	 both	 channels	
and	this	compound	seems	to	be	more	potent	on	KCNT1	channels:	 in	fact,	the	EC50	for	
KCNT1	is	109	µM,	while	the	EC50	for	KCNT2	is	331	µM	[Tejada	et	al.,	2012].	Two	other	
blockers,	 namely	 bepridil	 and	 quinidine,	 inhibit	 KCNT1	 currents	 in	 a	 concentration-
dependent	 manner	 and	 decrease	 channel	 activity	 in	 excised	 membrane	 patches.	
Similarly	 to	 oocytes,	 the	 application	 of	 quinidine	 (1	 µM-10	 mM)	 in	 HEK293	 cells	
expressing	KCNT1	produced	a	rapid	decrease	in	current	amplitude,	with	an	EC50	of	89.6	
µM	 [Yang	 et	 al.,	 2006].	 The	 KCNT1	 currents	 are	 also	 sensitive	 to	 bepridil-induced	
blockade,	with	the	latter	being	more	potent	than	quinidine	(EC50	of	1.0	µM)	[Yang	et	al.,	








described	 was the bis-phenol	 anti-parasitic	 compound	 bithionol,	 which	 in	 KCNT1-
expressing	HEK	cells	produces	a	 robust	 increase	 in	current	amplitude,	whit	an	EC50	of	
0.77	µM	[Yang	et	al.,	2006].	Similar	bithionol-induced	current	increases	are	observed	in	
KCNT1-expressing	 oocytes	 and	 for	 native	 KNa	 currents	 in	 neurons	 of	 the	 auditory	
brainstem.	 Bithionol	 reversibly	 activates	 KCNT1	 channels	 even	 when	 applied	 to	 the	
extracellular	face	of	excised	patches;	however,	bithionol	is	not	selective	for	KNa	channels	
because	it	also	activates	SLO1	calcium-activated	potassium	channels	[Yang	et	al.,	2006;	
Yang	 et	 al.,	 2007].	 A	 screen	of	 pharmacologically	 active	 compounds	using	 a	 rubidium	
flux	assay	against	KCNT1	channels	expressed	in	Chinese	Hamster	Ovary	(CHO)	cells	has	
revealed	 new	 activators:	 these	 include	 riluzole,	 loxapine,	 an	 antipsycotic	 agent,	 and	
niclosamide,	an	anthelmintic	agent	(Figure	8).	Loxapine	was	found	to	be	more	selective	
than	 bithionol	 since	 no	 effects	 on	 SLO1	 calcium-activated	 potassium	 channels	 were	
observed.	 Electrophysiological	 experiments	 revealed	 that	 loxapine	 is	 effective	 on	
recombinant	human	and	rat	KCNT1	channels	and	that	it	activates	native	KNa	channels	in	
isolated	DRG	neurons	[Biton	et	al.,	2012].		
Furthermore,	 KCNT2	 channels	 can	 be	 activated	 by	 fenamates	 such	 as	 niflumic	 acid	
(NFA,	 Figure	 6),	 even	 in	 the	 absence	 of	 intracellular	 Na+.	 In	Xenopus	 oocytes,	 KCNT2	
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patient	with	 state-of-the-art	 technologies	 as	 pathogenic,	 requires	 the	 convergence	of	





pathogenetic	 mechanisms,	 in	 the	 present	 Doctoral	 Thesis,	 I	 have	 investigated	 the	
biochemical,	functional,	and	pharmacological	properties	of	KCNT1	and	KCNT2	channels	
carrying	 mutations	 identified	 in	 patients	 affected	 by	 Epileptic	 Encephalopathy.	 The	
genetic	variants	investigated	in	the	present	study	are	listed	in	following	Table:		
	










KCNT1/SLO2.2	 c.1546	A>G	 p.	M516V	 [Rizzo	et	al.,	2016]	
KCNT1/SLO2.2	 c.2677	G>A	 p.	E893K	 newly-identified	
KCNT1/SLO2.2	 c.2849	G>A	 p.	R950Q	 Moller	et	al.,	2016	
KCNT2/SLO2.1	 c.1451	G>A	 p.	C484Y	 newly-identified	
KCNT2/SLO2.1	 c.569	G>C	 p.	R190H	 newly-identified	
KCNT2/SLO2.1	 c.569	G>C	 p.	R190P	 [DDDS,	Nature	2017]	
	





In	particular,	 I	have	studied	four	mutations	 (G288S,	M516V,	E893K	and	R950Q)	 in	the	
KCNT1	gene	and	three	mutations	(C484Y,	R190H	and	R190P)	in	the	KCNT2	gene.	Among	
them,	 two	 KCNT1	mutations	 (G288S	 and	 R950Q)	 have	 already	 been	 reported	 in	 the	
literature	[Ishii	et	al.,	2013;	Moller	et	al.,	2015].	The	identification	of	KCNT1	mutations	
has	been	made	possible	thanks	to	collaboration	with	a	multidisciplinary	team	formed	by	
child	 neurologists	 and	 human	 geneticists.	 Two	 MMPSI-affected	 patients	 have	 been	
identified	by	Prof.	G.	Coppola,	who	described	this	disease	for	the	first	time	[Coppola	et	
al.,	1995],	dr.	G.	Casara	 (Department	of	Pediatrics,	Regional	Hospital	of	Bolzano),	and	
dr.	M.	Vecchi	 (Department	of	Child	and	Mother	Health,	University	of	Padua);	 in	 these	
patients,	 the	genetic	analysis	performed	by	 the	group	of	Prof.	A.	Weisz	 (University	of	
Salerno)	identified	the	recurrent	KCNT1-G288S	and	the	novel	KCNT1-M516V	mutations.	
In	 addition,	 the	novel	 KCNT1-E893K	 variant	has	been	 identified	by	 the	group	of	dr.	 J.	
DiFrancesco	 at	 the	 “Carlo	 Besta”	 Institute,	 while	 the	 recurrent	 KCNT1-R950Q	 variant	








Figure	9	Schematic	 topology	of	a	KCNT1	 (SLO2.2)	channel	subunit	and	 location	of	 the	mutations	studied	 in	 the	
present	work.	Colored	circles	indicate	the	location	of	the	mutations	investigated:	the	G288S	mutation	(blue	circle)	
is	 localized	 in	the	S5	segment	of	the	channel,	while	the	other	mutations	are	 located	 in	the	C-terminal	region.	The	
M516V	mutation	(green	circle)	fall	in	the	RCK1	(Regulator	of	K+	conductance)	domain	of	the	KCNT1	subunits,	while	




Also	KCNT2	mutations	herein	 investigated	have	been	 identified	 through	a	network	of	
collaboration	 in	 Italy	 and	 abroad:	 in	 particular,	 the	 KCNT2-R190H	 variant	 has	 been	
identified	in	collaboration	with	the	Prof.	Johannes	Lemke	(Germany),	while	the	KCNT2-
R190P	 variant	was	 recruited	 through	 the	Deciphering	Developmental	Disorders	 Study	
[DDDS,	Nature	2017].	In	addition,	I	have	also	investigated	the	functional	consequences	
of	 another	 variant	 in	 KCNT2	 (C484Y)	 found	 in	 a	 patient	 with	 Autosomal	 Dominant	
Nocturnal	 Frontal	 Lobe	 Epilepsy	 (ADFNLE)	 and	 identified	 by	 Prof.	 Francesca	 Bisulli	
(University	of	Bologna);	this	variant	has	been	inherited	from	father’s	patient.	As	shown	
in	 Figure	 10,	 the	 C484Y	 mutation	 falls	 within	 the	 C-terminal	 region	 of	 the	 KCNT2	





























1.	engineering	of	mutations	 in	a	plasmid	containing	 the	cDNA	 for	a	 turbo-GFP	 tagged	
human	isoform	of	KCNT2	(RC216225;	Origene,	Rockville,	MD,	USA);	
2.	 biochemical	 studies	 by	 using	CHO	or	HEK-293	 total	 lysates	 in	 order	 to	 identify	 the	
most	efficient	heterologous	expression	system	for	KCNT2	subunits;	
3.	 patch-clamp	 recordings	 of	 macroscopic	 currents	 from	 Human	 Embryonic	 Kidney	
(HEK-293)	cells	transiently-transfected	with	wild-type	or	mutant	subunits,	in	homomeric	
or	heteromeric	configurations	with	wild-type	and	mutant	KCNT2	subunits;	
4.	 patch-clamp	 recordings	 of	 macroscopic	 currents	 in	 the	 presence	 of	 the	 KCNT2-
blocker	 quinidine	 in	 order	 to	 evaluate	 its	 ability	 to	 restore	 the	 functional	 alteration	
induced	by	the	presence	of	each	mutation;	







Each	 KCNT1	 mutation	 was	 engineered	 by	 Quick-change	 Site-Directed	
Mutagenesis	 (Agilent	Technologies)	 in	 a	pCMV6-KCNT1	 (RC214820;	Origene,	Rockville,	
MD,	USA)	plasmid	containing	the	cDNA	for	myc-DDK	tagged	human	transcript	variant	of	
KCNT1	(accession	number:	NM_020822;	1256	aminoacids).	
Similarly,	 mutations	 in	 KCNT2	 gene	 were	 obtained	 by	 Quick-change	 Site-Directed	
Mutagenesis	 in	 a	 pCMV6-KCNT2	 plasmid	 (RG216225;	 Origene,	 Rockville,	 MD,	 USA)	
encoding	 for	 the	 tGFP-tagged	 human	 transcript	 variant	 of	 KCNT2	 (accession	 number:	
NM_198503;	1135	aminoacids).	
The	mutations	were	engineered	 in	each	plasmid	by	Polymerase	Chain	Reaction	 (PCR),	






















































this	 step,	 the	 cells	were	 seeded	 into	 LB+agar	plates	 (containing	10g/L	 tryptone,	5	g/L	
yeast	 extract,	 5	 g/L	 NaCl,	 agar	 15	 g/L)	 containing	 the	 specific	 antibiotic	 to	 which	
plasmids	are	resistant	(in	our	experiments	ampicillin	100	µg/µL)	to	allow	the	selective	
growth	of	E.coli	cells	transformed	with	myc-DDK	pCMV6-KCNT1	or	tGFP-pCMV6-KCNT2.	
Plates	 were	 then	 incubated	 upside	 down	 at	 37°C	 for	 about	 17h	 to	 allow	 bacterial	
growth.		
Each	colony	grown	on	the	LB	medium	was	inoculated	in	6	mL	of	fresh	LB	medium	with	
ampicillin	 for	 selection,	 at	 37°C/220	 rpm	overnight.	 	 Plasmidic	DNA	was	 extracted	 by	
using	a	commercially	available	kit	(NucleoSpin	Plasmid	EasyPure,	Promega,	Milan,	Italy).	
The	 successful	 insertion	 of	 each	 desired	 mutation	 was	 verified	 by	 direct	 sequencing	
(Eurofins	Genomic,	Milan,	 Italy).	 In	order	to	obtain	a	 large	amount	of	DNA,	one	of	the	
positive	 clones,	 was	 amplified	 on	 a	 large	 scale	 (500	 mL)	 and	 plasmidic	 DNA	 was	
obtained	 by	 using	 a	 commercially	 available	 kit	 (PureYield	 Plasmid	 Maxiprep	 System,	





CHO	 (Chinese	 Hamstery	 Ovary)	 or	 HEK-293	 (Human	 Embryonic	 Kidney)	 cells	 were	
grown	 in	plastic	Petri’s	dishes	 (100	mm,	60	mm	or	40	mm,	according	 to	 the	different	
experimental	 procedures)	 in	 DMEM	 (Dulbecco’s	 Minimum	 Eagle	 Medium)	
supplemented	with	10%	Fetal	Bovine	Serum	(FBS)	decomplemented	at	56°C	for	30’,	1%	
L-glutamine	 (2	 mM	 in	 0.85%	 NaCl),	 1%	 penicillin	 (50	 U/mL)	 and	 streptomycin	 (50	
µg/mL)	in	a	humidified	atmosphere	at	37°C	with	5%	CO2.	The	CHO	cells	were	transiently	
transfected	 using	 Lipofectamine	 2000,	 according	 to	 the	 manufacturer	 protocol	
(LifeTechonologies,	Milan,	 Italy).	 In	each	 transfection	 reaction,	a	plasmid	encoding	 for	







	For	 electrophysiological	 experiments,	 CHO	 or	 HEK-293	 cells	 were	 seeded	 on	
glass	coverslips,	previously	heat	sterilized	and	pre-coated	with	poly-L-lysine,	 in	40	mm	
dishes.	The	day	after,	cells	were	transiently	transfected	with	4	µg	of	total	cDNA	(3.6	µg	
of	 plasmids	 coding	 for	 KCNT1	or	 KCNT2	 channels	 +	 0.4	µg	of	 EGFP)	 and	macroscopic	
currents	were	recorded	after	24	h	at	room	temperature	(22°-24°	C)	by	using	the	patch-




solution	 containing	 (in	mM):	 130	 KCl,	 10	NaCl,	 10	HEPES,	 5	 EGTA,	 5	Mg-ATP,	 pH	 7.4	



















Bepridil	 and	 quinidine	 (Sigma	 Aldrich,	 Milan,	 Italy)	 were	 dissolved	 in	 DMSO	 and	









In	 order	 to	 carry	 out	 biotinylation	 and	Western-blotting	 experiments,	 CHO	 cells	were	





at	 plasma	 membrane.	 Cells	 were	 washed	 three	 times	 with	 PBS	 (Phosphate	 Buffer	





and	 1X	 protease	 inhibitors	 (Roche,	Milan,	 Italy).	 An	 equal	 amount	 of	 cell	 lysates	was	
reacted	 with	 ImmunoPure	 immobilized	 streptavidin	 beads	 (Pierce)	 for	 30’	 at	 4°C	 to	
allow	the	binding	of	biotin	to	the	surface	of	the	magnetic	beads.	The	beads	(bound	to	







an	 equal	 amount	 of	 total	 lysates	 among	 different	 samples	 were	 separated	
electrophoretically	at	RT	on	7%	SDS-PAGE	gels	in	running	buffer	(containing	25	mM	Tris,	
192	mM	glycine,	0.1%	SDS)	until	the	complete	separation	of	the	protein	marker	loaded	
in	 parallel	 (Biorad,	 Milan,	 Italy).	 Proteins	 were	 then	 transferred	 onto	 polyvinylidene	
fluoride	membranes	(PVDF,	Biorad,	Milan,	Italy)	in	transfer	buffer	containg	25	mM	Tris,	
192	mM	glycine,	20%	methanol).	PVDF	membranes	were	than	incubated	with	5%	milk	









solution,	 GE	 Healthcare,	 UK)	 for	 1	 h	 at	 RT.	 The	 secondary	 antibodies	 are	 coniugated	
with	 horseradish	 peroxidase	 enzyme	 (HRP),	 which	 allows	 the	 emission	 of	 light	 in	
presence	 of	 an	 enhanced	 chemiluminescence	 solutions	 (ECL,	 Promega,	Madison,	WI,	



















6.1	 Clinical	 features	 of	 patients	 affected	 by	 Epileptic	 Encephalopathy	
carrying	KCNT1	or	KCNT2	mutations	
	





















Seizure	 onset	 characterized	 by	 an	
episode	 of	 sudden	 crying,	
psychomotor	 arrest	 of	 short	
duration	 followed	 by	 prolonged	
lethargy.	 Seizures	 characterized	 by	
deviation	 of	 the	 head	 to	 the	 right	
during	 sleep,	 followed	 quickly	 by	
heads	and	eyes	 turning	 to	 the	 left,	
together	 with	 tonic	 contraction	 of	

















Seizure	 activity	 characterized	 by	
apnoea	 and	 cyanosis.	 Focal	 motor	
seizures	 with	 clonic	 movements.	
EEGs	 recorded	 multifocal	
paroxysmal	 activity	 with	 shifting	
areas	 of	 ictal	 onset	 (migrating	
spikes)	 between	 hemispheres	 or	
overlapping	 seizures	with	 different	






















asynchrony,	 right	 central	 and	 left	
temporal	 slow	 waves	 and	 sharp	
spikes	 and	 waves.	 Seizures's	
frequency	 gradually	 increased	 up	
to	 30	 episodes	 per	 day,	
characterized	 by	 head	 and	 gaze	
deviation	 (right>left),	 winking,	 oral	
automatisms,	 sometimes	
associated	 with	 asymmetric	 upper	
limb	 flexor	 hypertonia	 (right>left).	
At	 four	 months	 of	 age	 he	
developed	 epileptic	 spasms	 with	
hypsarithmic	 pattern.	 At	 9	months	
of	 age,	 he	 presented	 clinical	 and	














Clinical	 features	 of	 patients	













Apneas	 and	 cyanosis,	 sometimes	
associated	 with	 pedaling	
movements	 and	 motor	 agitation.	
Epilepsy	relapsing	at	the	age	of	two	
months	 with	 focal	 myoclonus	 and	
focal	 tonic-clonic	 seizures	 at	 the	
lower	 limbs	 related	 to	 a	 EEG	
central	 ictal	 activity,	 with	
progressively	 increasing	 seizure	































Clusters	 of	 symmetric	 epileptic	
spasms	 and	 developmental	 arrest.	













Abnormal	 activity	 in	 the	 right	
temporal	 region.	 Grand	 mal	
convulsion	 at	 6	 months.	 She	 was	
also	lax	and	hypotonic.	Speech	was	
delayed.	 She	 has	 severe	 learning	
disability.	 She	 also	 self-harms	 with	















using	Whole	 exome	 sequencing	 (WES)	 technique	 allowed	 the	 identification	 of	 a	 new	
heterozygous	missense	mutation	c.1546	A>G	 (p.	M516V)	 in	proband	1,	but	not	 in	his	
healthy	parents.	The	M516	residue	is	located	in	the	RCK1	(Regulator	of	Conductance	for	




Figure	 13	 Identification	 of	 the	M516V	 and	 G288S	 heterozygous	 mutations	 found	 in	 two	 patients	 affected	 by	







To	 investigate	 the	 functional	 consequences	 of	 G288S	 and	 M516V	 mutations,	
electrophysiological	 experiments	were	 performed	 in	 CHO	 cells	 transiently	 transfected	
with	 plasmids	 encoding	 wild-type	 or	 mutant	 KCNT1	 subunits.	 The	 measurement	 of	
currents	elicited	by	wild-type	or	mutant	channels	were	performed	in	CHO	cells,	which	




0.6	 pA/pF	 n=5;	 Fig.	 14	 A,B).	 By	 contrast,	 CHO	 cells	 transfected	with	wild-type	 KCNT1	
cDNA	elicited	robust,	outwardly-rectifying	currents	 in	response	to	depolarizing	voltage	
pulses	 from	 -90	mV	 to	 +60	mV.	 Current	 density	 in	 KCNT1-transfected	 CHO	 cells	 was	
112.2±15.7	pA/pF	(+60	mV;	n=14;	Fig.	14	A,B).	The	application	of	tetraethylammonium	
(TEA,	 10	 mM)	 reversibly	 inhibited	 KCNT1	 currents	 by	 47±4%	 (+40	 mV;	 n=5).	 KCNT1	
currents	display	complex	activation	kinetics,	with	an	 instantaneous,	 time-independent	
component	 (Iinst),	 followed	 by	 a	 slower,	 time-dependent	 one	 (Isteady-state	 –	 Iinst).	 At	 +60	
mV,	the	ratio	between	currents	measured	at	the	beginning	(Iinst)	and	at	the	end	(Isteady-
state)	was	 0.28±0.01;	 (n=30).	 Electrophysiological	 experiments	 in	 CHO	 cells	 transiently	
expressing	KCNT1	channels	carrying	the	G288S	or	the	M516V	mutations	revealed	that	
all	mutant	 channels	 also	 generated	outwardly-rectifying	 currents.	When	 compared	 to	
wild-type	 KCNT1	 channels,	 current	 densities	 elicited	 by	 G288S	 and	 M516V	 mutant	
channels	at	+60	mV,	were	significantly	larger,	being	269.8±15.3	pA/pF	and	170.3±17.0	
pA/pF,	 respectively	 (n=14-19;	 p<0.05	 vs	 KCNT1;	 Fig.	 14	 A,	 B).	 No	 mutation-induced	
changes	 in	 channel	 selectivity	 for	 K+	 ions	were	observed:	 in	 fact,	 the	 current	 reversal	
potentials	estimated	 from	tail	 current	analysis	were	 -68.4±1.2	mV	 (n=11),	 -	68.7±0.9	
mV	 (n=13)	 and	 -68.9±1.3	mV	 (n=17)	 for	wild-type	 KCNT1,	 KCNT1-G288S	 and	 KCNT1-
M516V	 channels,	 respectively.	 These	 values	 are	 similar	 to	 those	 reported	 in	 the	
literature	for	SLO2.2	currents	expressed	in	Xenopus	laevis	oocytes	and	recorded	under	
similar	ionic	conditions	[Santi	et	al.,	2006].	In	KCNT1-G288S	and	KCNT1-M516V	mutant	
channels,	 the	 Iinst/Isteady-state	 were	 increased	 when	 compared	 to	 wild-type	 KCNT1	
channels	 (0.81±0.04	 and	 0.70±0.03,	 respectively;	 n=11-18;	 p<0.05).	Moreover,	 both	
mutations	were	able	to	induce	a	shift	of	the	G/V	curves	in	the	hyperpolarizing	direction.	
Boltzmann	 analysis	 of	 the	 G/V	 curves	 form	 KCNT1,	 KCNT1-G288S	 and	 KCNT1-M516V	
mutant	 channels	 revealed	 that	 the	 activation	 midpoints	 (V1/2)	 were,	 respectively,	
17.5±2.1	 mV,	 -10.5±1.6	 and	 -16.8±1.7,	 whereas	 the	 slopes	 (ks)	 were,	 respectively,	
23.9±1.0,	 23.0±1.1	 and	 21.1±1.2	mV/e-fold.	 Collectively,	 these	 results	 indicate	 that	
KCNT1-G288S	and	KCNT1-M516V	mutations	induce	a	strong	gain-of-function	effect	on	
KCNT1	channels.	
In	 order	 to	 study	 a	 possible	 mutation-induced	 altered	 sensitivity	 to	 regulation	 by	
	 48	
intracellular	 cations,	 patch-clamp	 recordings	were	 performed	 in	 CHO	 cells	 transiently	
expressing	 wild-type	 or	 mutant	 channels	 in	 the	 presence	 (10	 mM	 [Na+]i)	 or	 in	 the	
absence	of	[Na+]i.	When	NaCl	was	omitted	from	the	pipette	solution,	wild-type	KCNT1	





G288S	 and	 154.6±11.5	 pA/pF	 and	 77.2±12.5	 pA/pF	 for	 KCNT1-M516V.	 During	 the	
entire	 time	 of	 recordings,	 current	 density	 carried	 by	 ion	 channels	 regulated	 by	
intracellular	factors,	as	in	the	case	of	KCNT1	currents,	may	change	as	a	function	of	time;	
this	may	occur	because	 intracellular	dialysis	of	 the	pipette	solution	might	 significantly	
change	the	intracellular	content	of	ions	like	Na+	and	Cl-,	which	modulate	KCNT1	channel	
function.	Thus,	there	was	a	possibility	that	the	differences	in	current	densities	observed	
between	wild-type	and	mutant	KCNT1	channels	might	have	been	due	to	 the	 fact	 that	
the	 measurements	 were	 carried	 out	 at	 different	 time	 points	 after	 establishing	 the	
whole-cell	 configuration.	 Therefore,	 currents	 elicited	 by	 wild-type	 or	 mutant	 KCNT1	
subunits	 were	 measured	 as	 a	 function	 of	 the	 time	 (from	 1	 to	 5	 minutes)	 after	 the	
whole-cell	 access	 at	 0	mV.	 As	 demonstrated	 in	 Figure	 14	 D,	 current	 amplitudes	 and	
kinetic	 properties	 of	 wild-type	 or	 mutant	 subunits	 were	 stable	 during	 the	 entire	














as	 indicated	 in	 response	 to	 the	 voltage	 protocol	 shown	 above	 traces	 from	 NT	 cells.	 The	 arrows	 on	 the	 voltage	
protocol	 indicate	 the	 time	 chosen	 for	 current	 analysis	 (Iinst=	 instantaneously-activated	 currents;	 Iss=	 current	
measured	at	 the	steady-state	 level).	 (B)	Current	density	 (left)	and	normalized	conductance	 (right)	of	wild-type	or	
mutant	 KCNT1	 channels,	 as	 indicated,	 recorded	with	 10	mM	NaCl	 in	 the	pipette	 (10	mM	Na+).	 Each	point	 is	 the	
mean	±	SEM	of	5	(NT),	14	(KCNT1),	15	(KCNT1	G288S)	or	19	(KCNT1	M516V)	determinations,	performed	in	at	least	
three	different	transfections.	(C)	Current	density	of	wild-type	and	mutant	KCNT1	channels,	recorded	without	NaCl	in	
the	pipette	 solution	 (0	mM	Na+).	 Each	point	 is	 the	mean	±	 SEM	of	11	 (KCNT1),	20	 (KCNT1	G288S)	or	12	 (KCNT1	
M516V)	determinations,	performed	in	at	least	three	different	transfections.	(D)	On	the	left,	representative	current	







To	 evaluate	whether	 the	 strong	 gain-of-function	 effects	 of	 KCNT1-G288S	 and	 KCNT1-
M516V	mutant	subunits	were	due	to	an	alteration	in	total	or	plasma	membrane	protein	
expression	 levels,	 western-blotting	 experiments	 were	 performed	 on	 total	 lysates	 or	
biotinylated	plasma	membrane	fractions	obtained	from	CHO	cells	transiently	expressing	
myc-DDK	 tagged	wild-type	 and	mutant	 KCNT1	 subunits	 (Figure	 15).	Western-blotting	
experiments	 of	 total	 protein	 lysates	 from	 CHO	 cells	 transfected	 with	 wild-type	 or	
mutant	 subunits	 revealed	 the	 expression	 of	 a	 specific	 band	 of	 ~	130	 kDa,	 a	 value	
consistent	 with	 the	 predicted	 molecular	 mass	 of	 a	 KCNT1	 subunit.	 Densitometric	
analysis	revealed	that	the	intensity	of	this	band	was	identical	in	lysates	from	KCNT1	and	
KCNT1	 G288S-transfected	 cells,	 whereas	 it	 was	 lower	 in	 KCNT1	 M516V-transfected	
cells.	 The	 ODKCNT1-TOT/ODTUB	 ratios	 were	 1.38±0.21;	 1.16±0.20	 and	 0.64±0.14	
respectively	in	the	three	groups	(n=7;	p<0.05).	Similar	results	were	obtained	in	western-	
blotting	experiments	performed	in	biotinylated	plasma	membrane	fractions.	In	fact,	the	








blotting	 experiments	 performed	 on	 total	 lysates	 (upper	 panels)	 or	 plasma	 membrane-enriched	 fraction	 (lower	
panels)	 obtained	 from	CHO	 cells	 untransfected	 (NT)	 or	 expressing	wild-type	 or	mutant	 subunits,	 as	 indicated.	 In	
each	panel,	the	higher	blots	were	probed	with	anti-DDK	antibodies	to	reveal	the	KCNT1	channels	(130	kDa),	while	
the	lower	panels	were	probed	with	anti-a-tubulin	(50	kDa),	to	check	for	equal	protein	loading	and	to	confirm	that	
the	 biotin	 did	 not	 leaks	 into	 the	 cell	 and	 labels	 intracellular	 proteins.	 Numbers	 on	 the	 left	 correspond	 to	 the	
molecular	masses	of	the	protein	marker.		
	
These	 results	 suggest	 that	 the	M516V,	but	not	 the	G288S	mutation,	 reduced	 subunit	




the	 identical	 absolute	 ratio	 between	 plasma	 membrane	 and	 total	 protein	 in	 cells	
expressing	 KCNT1,	 KCNT1	 G288S	 or	 KCNT1	M516V:	 the	 ODKCNT1-BIOT/ODKCNT1-TOT	 ratios	
were	1.29±0.16,	1.87±0.70	and	2.06±0.74	respectively	(n=6-7;	p<0.05).		











mutations	herein	 investigated	were	 found	heterozygously	 in	 the	KCNT1	gene.	For	 this	
reason,	to	mimic	the	genetic	condition	of	these	MMPSI-affected	patients,	wild-type	and	
mutant	KCNT1	cDNAs	were	co-transfected	in	CHO	cells	at	a	0.5:0.5	ratios.	As	shown	in	
Figure	 16,	 currents	 elicited	 from	 KCNT1/KCNT1	 G288S	 and	 KCNT1/KCNT1	 M516V	
heteromers	were	still	 larger	than	those	from	KCNT1	homomers	 (p<0.05),	but	reduced	




and	mutant	KCNT1	channels.	Representative	current	traces	 (left	 three	panels)	and	pooled	current	densities	 from	
CHO	cells	expressing	KCNT1	homomers	or	KCNT1+KCNT1-G288S	or	KCNT1+KCNT1-M516V	heteromers,	as	indicated	





respectively	 (p<0.05),	 for	 KCNT1/KCNT1	 G288S,	 KCNT1/KCNT1	 M516V	 and	 KCNT1	
channels	(p<0.05	versus	KCNT1).	The	fact	that	current	density	values	and	Iinst/Isteady-state	
ratios	 in	 cells	 expressing	 heteromeric	 wild-type/mutant	 channels	 were	 smaller	 than	
those	 recorded	 in	 cells	 expressing	mutant	 homomers	 allows	 to	 hypothesize	 that	 the	











6.6	 Pharmacological	 characterization	 of	 G288S	 and	 M516V	 mutant	
channels		
 




of	 10-1000	 µM	 (Figure	 17	 B).	 Both	 drugs	 produced	 a	 concentration-dependent	
decrease	 in	 KCNT1	 outward	 currents	 with	 IC50s	 at	 +60	 mV	 of	 1.1	 ±	 0.1	 µM	 and	
82.1±14.3	µM,	respectively.	Both	bepridil	and	quinidine	inhibited	KCNT1	currents	over	
the	 entire	 voltage	 range	 of	 activation,	 although	 the	 blocking	 potency	 was	 slightly	
smaller	 at	 less	 depolarized	 voltages	 (at	 -20	mV,	 the	 IC50s	 for	 bepridil-	 and	 quinidine-
induced	 KCNT1	 blockade	 were	 2.8±1.6	 µM	 and	 157±20	 µM	 respectively).	 When	
compared	to	KCNT1,	bepridil	was	even	more	potent	 in	blocking	KCNT1-G288S	 (in	 fact	
IC50s	 was	 0.15±0.05	 µM;	 p<0.05	 versus	 KCNT1)	 or	 KCNT1-M516V	 (IC50s	 was	
0.3±0.1	µM;	 p<0.05	 versus	 KCNT1)	 channels.	When	 quinidine	was	 tested	 on	mutant	
KCNT1	 channels,	 a	 similar	 trend	 was	 also	 observed,	 although	 differences	 were	 less	
pronounced	 and	 failed	 to	 reach	 statistical	 significance.	 In	 fact,	 quinidine	 IC50s	 were	
46±12	 µM	 and	 67±19	 µM	 for	 KCNT1-G288S	 (p=0.057	 versus	 KCNT1)	 and	 KCNT1-
M516V	 channels	 (p=	 0.54	 versus	 KCNT1),	 respectively.	 Notably,	 when	 bepridil	 or	
quinidine	were	tested	up	to	0.1	µM	and	10	µM	respectively,	no	current	inhibition	was	




















M516V	 mutations	 and	 to	 deepen	 knowledge	 on	 pathogenic	 aspects	 of	 KCNT1	 gene	
variants	 in	 epileptic	 encephalopathies,	 we	 investigated	 the	 effects	 induced	 by	 two	







KCNT1	 subunits	 of	 different	 species	 (h=human,	 r=rat,	 m=mouse,	 g=chicken,	 x=Xenopus	 laevis,	 c=cat,	 s=sheep,	
z=zebrafish.			
 
Western-blotting	 experiments	 performed	 in	 total	 lysates	 of	 CHO	 cells	 transiently	
expressing	 wild-type	 or	 mutant	 subunits	 revealed	 that	 the	 presence	 of	 E893K	 and	
R950Q	 mutations	 does	 not	 interfere	 with	 the	 expression	 levels	 of	 KCNT1	 subunits	










blotting	experiments	performed	on	total	 lysates	obtained	from	untransfected	 (NT)	CHO	 	or	 transfected	CHO	cells	
expressing	KCNT1,	KCNT1-E893K	or	KCNT1-R950Q	mutant	 subunits.	 The	higher	blot	was	probed	with	 anti-KCNT1	





to	 KCNT1-transfected	 cells:	 in	 fact,	 current	 densities	 were	 229.0±20.3	 pA/pF	 and	
231.3±21.1	pA/pF,	respectively	(n=21;	p<0.05	versus	wild-type	KCNT1).	Furthermore,	in	
both	 KCNT1-E893K	 and	 KCNT1-R950Q	 mutant	 channels,	 the	 Iinst-Isteady-state	 ratio	 was	
increased	 when	 compared	 to	 KCNT1,	 being	 0.81±0.03	 and	 0.44±0.04,	 respectively	
(n=13-20;	p<0.05	versus	wild-type	KCNT1	channels).	The	G/V	curves	 for	KCNT1	E893K	
and	 R950Q	 were	 shifted	 in	 the	 hyperpolarizing	 direction:	 accordingly,	 Boltzmann	
analysis	 of	 the	 G/V	 curves	 from	 KCNT1,	 KCNT1-E893K	 and	 KCNT1-R950Q	 mutant	
channels	revealed	that	the	activation	midpoint	(V1/2)	was,	respectively,	17.5±2.1	mV,	-





with	 the	 Na+-dependent	 KCNT1	 activation	 process,	 additional	 functional	 experiments	
were	performed	without	NaCl	in	the	pipette	solution.	The	results	obtained	showed	that			 
wild-type	KCNT1	currents	were	decreased	by	a	factor	of	~5,	whereas	those	from	KCNT1-	
E893K	 or	 KCNT1-R950Q	 channels	 were	 about	 2-	 or	 4.4-times	 smaller	 than	 those	








in	 the	 presence	 (10	mM	Na+)	 or	 in	 the	 absence	 of	Na+	were	 104.1±11.4	 or	 20.0±2.9	
pA/pF,	229.0±20.3	or	101.0±17.6	pA/pF,	and	231.3±21.1	or	52.3±10.5	pA/pF	for	KCNT1,	
KCNT1-E893K,	 and	 KCNT1-R950Q	 channels,	 respectively	 (p<0.05	 versus	 wild-type	
KCNT1	channels	(Figure	20	B,C).	These	results	suggest	that	both	KCNT1	mutations,	and	










transfections.	 (C)	Current	density	of	wild-type	and	mutant	KCNT1	channels,	 recorded	without	NaCl	 in	 the	pipette	









In	order	 to	verify	 the	possibility	 to	 counteract	 the	gain-of-function	effects	 induced	by	
E893K	or	R950Q	mutations,	the	well-known	KCNT1	current	blocker	quinidine	was	tested	
on	 CHO	 cells	 transiently	 expressing	 wild-type	 or	 mutant	 subunits.	 Quinidine	 was	
perfused	at	four	different	concentrations	(1	µM,	10	µM,	100	µM	or	1000	µM;	Figure	21	
A,	B,	C,	D).	
The	 perfusion	 of	 quinidine	 on	 currents	 elicited	 by	 KCNT1-E893K	 and	 KCNT1-R950Q	
mutant	channels	 induced	current	 inhibition,	with	higher	sensitivity	when	compared	to	
wild-type	KCNT1	channels.	In	fact,	IC50s	were:	81.8±0.1	µM,	9.6±2.5	µM	and	24.0±5.7	
µM	(n=19-28;	p<0.05).	 In	particular,	10	µM	quinidine	was	able	 to	 induce	a	 significant	
blockade	of	KCNT1-E893K	and	KCNT1-R950Q	currents,	without	affecting	those	elicited	
by	wild-type	KCNT1	channels.			
Collectively	 these	 results	 indicate	 that	 quinidine	 could	 be	 useful	 to	 counteract	 the	
excess	 of	 current	 elicited	 by	mutant	 channel	 subunits;	 in	 addition,	 the	 slightly	 higher	
potency	 of	 the	 drug	 in	 blocking	mutant	 versus	 wild-type	 KCNT1	 currents	 indicates	 a	


















To	 assess	 the	 functional	 effects	 of	 the	 KCNT2	mutations,	 biochemical	 and	 functional	
approaches	similar	to	those	applied	for	KCNT1	were	used	to	study	wild-type	or	mutant	
KCNT2	channels.		
Firstly,	 channels	 expression	 was	 assessed	 in	 two	 different	 heterologous	 expression	
systems.	Western	blotting	experiments	were	performed	in	total	 lysates	from	CHO	and	
HEK293	cells	transiently	expressing	wild-type	or	KCNT2-C484Y	mutant	channels.	
Wild-type	 and	 mutant	 KCNT2	 subunits	 were	 detected	 by	 using	 anti-turbo	 GFP	
antibodies:	 a	 single	 band	 of	 ~130	 kDa	 was	 detected	 in	 the	 lanes	 corresponding	 to	
lysates	of	HEK293	cells	expressing	wild-type	or	mutant	channels,	while	no	signals	were	
detected	 in	total	 lysates	of	CHO	cells	expressing	wild-type	or	mutant	KCNT2	channels,	
nor	 in	non-transfected	HEK293	or	CHO	cells.	 Furthermore,	 to	 check	 for	equal	protein	
loading,	the	same	lysates	were	probed	with	anti-g-tubulin	antibody	(50	kDa,	Figure	22).	
The	results	obtained	indicate	that	HEK293	cells,	but	not	CHO	cells,	are	efficient	in	vitro	






Figure	 22	 Biochemical	 characterization	 of	 wild-type	 or	 mutant	 KCNT2	 channels	 in	 two	 different	 heterologous	
expression	 systems.	 Representative	 images	 of	 western-blotting	 experiments	 on	 total	 lysates	 obtained	 from	
untransfected	 (NT)	CHO	or	HEK293	cells	or	 transfected	CHO	or	HEK293	expressing	wild-type	or	mutant	 subunits.	
The	higher	blots	were	probed	with	anti	turbo-GFP	antibodies	to	reveal	the	protein	of	interest	(135	kDa),	while	the	






was	 affected	with	ADNFLE	was	 able	 to	 induce	 functional	 changes	 in	 KCNT2	 channels,	
HEK	293	cells	were	transiently	transfected	with	plasmids	encoding	wild-type	or	mutant	




pA/pF;	 (n=52).	 KCNT2	 currents	 displayed	 complex	 activation	 kinetics,	 with	 an	
instantaneous,	 time-independent	 component	 (Iinst)	 followed	 by	 a	 slower,	 time-
dependent	one	(Isteady-state-Iinst).	At	+60	mV,	the	ratio	between	the	currents	measured	at	
the	beginning	(Iinst)	and	at	the	end	(Isteady-state-Iinst)	was	0.49±0.02	(n=52).	








respectively	 (p>0.05)	whereas	 the	slopes	 (ks)	were	respectively	13.0±0.6	and	11.7±0.5	
mV/e-fold	for	wild-type	KCNT2	and	KCNT2-C484Y	channels	(p>0.05).		






Figure	 23	 Functional	 characterization	 of	wild-type	 and	mutant	 C484Y	 KCNT2	 channels.	 (A)	 Current	 traces	 from	
HEK-293	 cells	 untransfected	 (NT)	 or	 transfected	 with	 expression	 vectors	 encoding	 wild-type	 or	 mutant	 KCNT2	
subunits,	 as	 indicated,	 in	 response	 to	 the	 voltage	 protocol.	 (B)	 Current	 density	 of	 wild-type	 and	mutant	 KCNT2	
channels.	Each	point	is	the	mean	±	SEM	of	2	(NT),	31	(KCNT2)	and	37	(KCNT2-C484Y)	determinations,	performed	in	















KCNT2	 proteins.	 Left,	 topological	 representation	 of	 a	 KCNT2	 subunits:	 gray	 boxes	 indicate	 transmembrane	
segments,	while	the	red	circle	and	arrow	indicate	the	position	of	the	mutated	residue	found	in	patients	affected	by	
Developmental	 and	 Epileptic	 Encephalopathy.	 Right,	 partial	 alignment	 of	 KCNT2	 orthologous	 among	 different	
species	(h=human;	r=rat;	m=mouse;	p=pig;	c=cat;	z=zebrafish).	The	end	of	the	S4	segment	and	the	beginning	of	S5	




Western-blotting	 experiments	 performed	 in	 total	 lysates	 of	 HEK-293	 cells	 transiently	
expressing	wild-type	or	mutant	subunits	revealed	that	the	presence	of	R190H	mutation	
does	 not	 interfere	 with	 the	 expression	 levels	 of	 KCNT2	 subunits,	 while	 a	 significant	
increase	in	the	expression	levels	were	observed	for	R190P	mutations	(Figure	25).	In	fact,	
the	 ODKCNT2-TOT/ODTUB	 ratios	 were:	 1.00±0.03	 for	 wild-type	 KCNT2,	 0.49±0.08	 for	





















In	 order	 to	 study	 the	 functional	 effects	 prompted	 by	 these	 mutations	 on	 KCNT2	
channels,	 patch-clamp	 experiments	 were	 performed	 in	 HEK-293	 cells	 transiently	
transfected	with	plasmids	encoding	wild-type	or	mutant	KCNT2	subunits.	
	Expression	of	KCNT2	channels	carrying	 the	R190H	or	 the	R190P	mutations	generated	

















steady-state	 level).	 Current	 scale:	 500	 pA;	 time	 scale	 20	 msec.	 (B,C)	 Current	 density	 (left)	 and	 normalized	




the	current	 reversal	estimated	 from	tail	 current	analysis	were	 -67.5±0.9	mV	(n=34),	 -
63.5±1.3	mV	 (n=14)	 and	 -62.7±1.0	mV	 (n=12)	 for	 KCNT2,	 KCNT2-R190H	and	KCNT2-
R190P	 channels	 respectively.	 In	 KCNT2	 R190P	 and	 R190H	 mutant	 channels,	 the	
Iinst/Isteady-state	 ratios	were	significantly	 increased	when	compared	to	KCNT2	 (0.77±0.02	
and	 0.93±0.01,	 respectively;	 n=49-24;	 p<0.05).	 The	 G/V	 curves	 for	 KCNT2,	 KCNT2-
R190H	 and	 KCNT2-R190P	 were	 shifted	 in	 the	 hyperpolarizing	 directions:	 Boltzmann	
analysis	 of	 the	 G/V	 curves	 from	 wild-type	 KCNT2,	 KCNT2-R190H	 and	 KCNT2-R190P	
mutant	 channels	 revealed	 that	 the	 activation	 midpoints	 (V1/2)	 were,	 respectively,	 -
	 68	
10.3±0.7	mV,	 -14.9	±1.8	mV	and	-48.0±2.3	mV,	 (p<0.05	versus	KCNT2),	whereas	the	
slopes	 (k)	 were	 respectively	 11.3±0.4,	 24.5±1.0	 and	 28.6±1.6	 mV/e	 fold;	 (n=24-52;	
p<0.05).	











+60	mV	were	 86.1±6.3	 pA/pF	 for	 KCNT2+KCNT2-R190H	 (n=17;	 p<0.05	 versus	 KCNT2	
and	 KCNT2-R190H)	 and	 250.2±16.2	 pA/pF	 for	 KCNT2+KCNT2-R190P	 (n=15;	 p<0.05	
versus	 KCNT2	 and	 KCNT2-R190P).	 Moreover,	 Iinst/Isteady-state	 ratios	 at	 +60	 mV	 were	
0.61±0.03	 for	 KCNT2+KCNT2-R190H	 (p<0.05	 versus	 KCNT2	 and	 KCNT2-R190H),	 and	
0.80±0.04	 for	 KCNT2+KCNT2-R190P	 (p<0.05	 versus	 KCNT2	 and	 KCNT2-R190P),	
respectively.	
Boltzmann	 analysis	 of	 the	G/V	 curves	 from	KCNT2+KCNT2-R190H	 and	 KCNT2+KCNT2-
R190P	 heteromeric	 channels,	 revealed	 that	 the	 activation	 midpoints	 (V1/2)	 were	 -
10.1±1.9	 mV	 and	 -40.4±2.9	 mV,	 respectively	 (p<0.05	 versus	 KCNT2),	 whereas	 the	
slopes	 (k)	 were	 21.1±1.2	 and	 27.8±2.0	 mV/e-fold	 for	 KCNT2+KCNT2-R190H	 and	
KCNT2+KCNT2-R190P	(p<0.05	versus	KCNT2).	
As	observed	for	KCNT1	mutations,	the	fact	that	current	density	values	and	Iinst/Isteady	state	
ratios	 in	 cells	 expressing	 heteromeric	 wild-type/mutant	 channels	 were	 intermediate	
between	 homomeric	 wild-type	 and	 mutant	 channels	 allows	 to	 hypothesize	 that	 the	
extent	of	mutation-induced	gating	changes	depends	on	the	number	of	mutant	subunits	













6.13	 Molecular	 modelling	 of	 the	 mechanism	 through	 which	 the	 R190	






resolution	 crystal	 structures	 of	 KCNT2	 channels	 are	 still	 unavailable,	 homology	
modelling	studies	were	performed	using	the	closed	and	open	configurations	of	chicken	
KCNT1	 channels	 resolved	 by	 cryo-electron	microscopy	 at	 4.5	 Å,	 as	 template	 [Hite	 et	
al.2015;	Hite	et	al.,	2017].	
As	highlighted	in	the	homology	model	shown	in	Figure	28	A,	in	the	closed	state	of	the	
channel,	 the	 R190	 residue,	 forms	 strong	 ionized	 hydrogen	 bounds	 with	 two	 regions	
which	do	not	belong	to	the	same	subunit.	In	particular,	the	R190	residue	may	interact	
with	 the	 side	 chain	 of	 the	 E283	 residue	 located	 in	 the	 S6	 and	 of	 the	 Q349	 residue	
located	in	the	RCK1	domain,	thus	promoting	the	stabilization	of	the	closed	state.	In	the	
open	 state	 of	 the	 channel,	 the	 interaction	 described	 above	 could	 not	 be	 detected	
(Figure	28	B).	
These	modelling	results	suggest	that	the	R190	mutation	may	selectively	destabilize	the	







Figure	 28	Homology	model	 of	 the	 closed	 state	 (A)	 and	 open	 state	 (B)	 of	 KCNT2	 channels.	 The	 R190	 residue	 is	






The	 KCNT2	 currents	 are	 blocked	 by	 quinidine	 in	 a	 concentration-dependent	manner.	
Therefore,	 to	evaluate	 the	possibility	 to	 counteract	 the	 functional	 alterations	 induced	
by	 the	presence	of	R190H	or	R190P	mutations	 in	KCNT2	channels,	we	 tested	10,	100	
and	1000	µM	quinidine	on	both	wild-type	and	mutant	KCNT2	subunits.	When	quinidine	
was	tested	on	wild-type	KCNT2	currents,	the	IC50	of	current	inhibition	at	+60	mV	was	44	
µM,	 being	 slightly	 more	 sensitive	 to	 drug-induced	 blockade	 compared	 to	 KCNT1	








Within	 the	 following	4	weeks,	 clinical	 status	of	 this	patient	 seems	 to	be	 improved.	 In	
particular,	 seizure	 frequency	was	 reduced	 from	daily	 to	 2-3	 events	 per	week	without	
apparent	side	effects.		
Given	the	above	mentioned	clinical	and	preclinical	data,	these	results	demonstrate	that	






Figure	 29	Pharmacological	 characterization	of	 the	 currents	 expressed	by	wild-type	or	mutant	KCNT2	 channels.	
(A,B,C	upper	panel)	Pooled	current	density	data	from	HEK-293	cells	expressing	wild-type	or	mutant	KCNT2	channels,	
as	 indicated,	 in	 control	 solution	 or	 upon	 exposure	 to	 quinidine	 at	 10,100	 or	 1000	µM.	 Lower	 panel,	 average	 of	
current	density	measured	at	+60	mV	from	HEK	cells	expressing	wild-type	or	mutant	KCNT2	channels,	as	indicated	in	









predisposition	 to	 generate	 seizures.	 This	 pathological	 condition	 often	 leads	 to	
neurobiological,	 cognitive,	 psychological,	 and	 social	 impairments	 in	 the	 affected	
patients.	 [International	 League	Against	 Epilepsy,	 2014].	 In	 a	 large	 fraction	 of	 epilepsy	
types,	genetic	mutations	in	several	genes	encoding	for	ion	channels,	receptors,	or	other	
proteins	have	been	identified.	
One	 of	 these	 is	 represented	 by	 the	 KCNT1	 gene,	 which	 codes	 for	 pore-forming	
a-subunits	 of	 Na+-dependent	 K+	 channels	 (KNa),	 that	 play	 an	 important	 role	 in	 the	
regulation	 of	 neuronal	 excitability	 [Battacharjee	 et	 al.,	 2005].	 The	 KCNT1	 channels	
together	 with	 the	 homologous	 KCNT2	 channels,	 belong	 to	 the	 SLO2	 family	 of	 Na+-
activated	 K+	 channels.	 KCNT1	 channels,	 as	 well	 as	 KCNT2	 channels,	 consists	 of	 six	
transmembrane	segments	(S1-S6)	and	an	extended	C-terminal	region	that	encompasses	
two	predicted	RCK	(regulators	of	conductance	of	K+)	domains.	These	subunits	assemble	
as	 tetramers	 to	 form	 functional	 channels,	 whose	 activation	 is	 only	 slightly	 voltage-
dependent	[Joiner	et	al.,	1998].	In	particular,	the	voltage-dependence	of	SLO2	channels	
activation	 seems	 to	be	 regulated	by	 the	 voltage-dependent	 binding	of	Na+	 ions	 in	 an	
intracellular	site,	at	least	in	part	located	in	the	RCK2	domain.			
KCNT1	 is	widely	expressed	throughout	the	brain,	as	well	as	 in	 the	dorsal	 root	ganglia,	
kidney	and	heart	[Kaczmarek	et	al.,	2013].	
	To	date,	de	novo	mutations	in	the	KCNT1	gene	have	been	reported	in	a	wide	range	of	
epileptic	 disorders,	 particularly	 in	 Malignant	 Migrating	 Partial	 Seizure	 of	 Infancy	
(MMPSI).	Mutations	 in	 the	 KCNT1	 gene	 have	 been	 also	 shown	 to	 be	 responsible	 for	
autosomal-dominant	and	sporadic	cases	of	nocturnal	frontal	lobe	epilepsy	[Heron	et	al.,	





In	 the	 present	 work,	 I	 have	 characterized	 the	 biochemical,	 functional	 and	
pharmacological	 properties	 of	 de	 novo	 heterozygous	 mutations	 in	 the	 KCNT1	 gene	
(Table	 6),	 found	 in	 patients	 affected	 by	 EEs.	 Almost	 all	 the	 KCNT1	mutations	 herein	
investigated	 are	 localized	 in	 the	 C-terminal	 region,	 particularly	 in	 the	 region	
encompassing	the	RCK	domains	of	the	channels.	By	contrast,	the	G288S	mutation	falls	










never	been	associated	with	human	disorders.	 In	particular,	 I	 studied	 the	effects	of	an	
inherited	KCNT2	variants,	found	in	a	patient	affected	by	ADNFLE	(C48AY)	and	the	effects	









a	 result	 consistent	 with	 most	 KCNT1	 mutations	 previously	 identified	 in	 other	 EE	
patients.	 The	 molecular	 basis	 of	 these	 effects	 can	 be	 multiple:	 western-blotting	
























































increase	 in	maximal	 current	does	not	appear	 to	be	 related	 to	 	 an	 increase	 in	 total	or	
plasma	membrane	abundance	of	KCNT1	subunits	carrying	specific	substitutions,	as	also	
reported	previously	for	other	epilepsy-causing	KCNT1	variants	[Kim	et	al.,	2014].			
Notably,	 computational	 analysis	 suggests	 possible	 changes	 in	 the	molecular	 structure	
and	 the	 ion	 channel	 property	 induced	 by	 the	 recurrent	 G288S	mutation.	 In	 fact,	 the	
G288S	substitution	introduces	a	hydrogen	bond	that	alters	the	pore	structure	domain,	
thus	altering	channel	function	[Ishii	et	al.,	2013].	A	reduction	in	the	unitary	conductance	
and	 an	 abolishment	 of	 subconductance	 states	 were	 also	 observed	 in	 KCNT1-G288S	
channels	[Kim	and	Kaczmarek,	2014].		
By	contrast,	no	structural	insights	are	available	to	understand	the	molecular	basis	of	the	
gain-of-function	 effects	 of	 the	 other	 KCNT1	mutations	 herein	 investigated;	 however,	
their	location	within	the	RCK	domains	and	the	alteration	in	the	Na+-sensitivity	observed	
for	 the	 currents	 elicited	 by	 KCNT1	 channels	 carrying	 each	 mutation,	 both	 suggest	 a	
plausible	 mutation-induced	 alteration	 in	 the	 RCK	 structure,	 therefore	 leading	 to	 an	
increased	channel	sensitivity	to	intracellular	Na+	ions.	In	addition,	the	KCNT1	C-terminal	





regulatory	 molecules	 acting	 upon	 the	 RCK	 domains;	 however,	 this	 hypothesis	 would	
merit	 further	 investigation.	 Finally,	 several	 cytoplasmic	 signaling	 pathways,	 such	 as	
those	mediated	by	FMRP	[Brown	et	al.,	2010],	which	regulates	neuronal	excitability	and	
protein	 translation	 [Zhang	 et	 al.,	 2012]:	 a	 possible	 alteration	 in	 the	 FMRP-induced	
KCNT1	current	modulation	prompted	by	the	KCNT1	mutants	herein	investigated	has	not	
been	studied,	but	could	not	be	excluded.	
	While	 several	 pathogenetic	 variants	 in	 the	 KCNT1	 gene	 have	 been	 identified	 in	 EEs	
patients,	 no	 evidence	 is	 yet	 available	 regarding	 a	 possible	 contribution	 of	de	 novo	 or	
inherited	KCNT2	variants	in	human	disorders.	In	this	study,	massive	parallel	sequencing	
in	 two	 patients	 with	 an	 overlapping	 spectrum	 of	 Developmental	 and	 Epileptic	
Encephalopathy	 (DEE)	 identified	 two	 pathogenic	 variants	 in	 the	 KCNT2	 gene,	 namely	
	 77	
R190H	and	R190P.	As	observed	for	mutations	in	KCNT1,	also	KCNT2	substitutions	at	the	
R190	 residue	 induce	 gain-of-function	 effects.	 Although	 high-resolution	 structures	 of	
KCNT2	 channels	 are	 still	 unavailable,	 homology	 modelling	 using	 closed	 and	 open	




this	 interaction	 could	 not	 be	 detected	 in	 the	 open	 configuration	 of	 KCNT2	 channels.	
These	 observations	 support	 the	 hypothesis	 that	 R190	 mutations	 would	 selectively	







roles	 played	 by	 K+	 channel	 in	 neuronal	 excitability.	 However,	 other	 epilepsy-causing	





specific	 function	 played	 by	 the	 different	 K+	 channels	 during	 ontogenesis	 at	 distinct	
cellular	 and	 subcellular	 sites.	 These	 include	 the	 regulation	 of	 neuron-astrocyte	 cross-
talking	[Sicca	et	al.,	2011],	enhanced	Na+	channels	repriming	by	faster	action	potentials	
repolarization	[Du	et	al.,	2005],	secondary	depolarizations	caused	by	over-activation	of	






preferential	 expression	 of	 Nav1.1	 channels	 in	 inhibitory	 interneurons,	 selective	
suppression	 of	 interneuronal	 excitability	 results	 in	 an	 altered	 balance	 between	




patient	with	 a	mild	phenotypic	 spectrum	disorder	 associated	 to	Autosomal	Dominant	
Nocturnal	 Frontal	 Lobe	Epilepsy	 (ADNFLE).	 This	 variant	 seems	 to	be	unable	 to	 induce	
dramatic	 effects	 on	 channel	 function	 and	 could	 be	 therefore	 classified	 as	 a	 KCNT2	
polymorphism.	Nonetheless,	many	reasons	could	be	taken	into	account	to	explain	such	
results	 (e.g.	 the	mutation	could	alter	complex	KCNT2	regulatory	pathways,	not	herein	
investigated);	 therefore,	 it	 should	 be	 highlighted	 that	 this	 variant	 has	 been	 inherited	
from	a	healthy	parent	and	the	clinical	phenotype	is	less	severe	than	those	reported	for	
the	other	KCNT2	mutations	herein	investigated.		
Our	 results	 on	 the	 pathogenetic	 role	 of	 KCNT2	 de	 novo	 variants	 in	 severe	
developmental	epilepsies	are	also	 in	 line	with	a	recent	study	which	reports	 the	F240L	
KCNT2	de	 novo	 variant,	 found	 in	 a	 patient	with	 epileptic	 encephalopathy.	 The	 F240L	
variant	seems	to	be	pathogenic	since	it	induces	functional	alterations,	though	they	are	
distinct	 from	those	herein	reported	for	KCNT2	R190H	or	KCNT2	R190P	mutations:	the	
substitution,	 falling	 in	the	pore	of	 the	channel,	 reduces	current	 inhibition	by	high	[Cl-]	
and	causes	 the	 loss	of	K+	 ions	selectivity	 [Gururaj	et	al.,	2017].	Further	studies	will	be	
necessary	 to	deepen	our	knowledge	on	the	pathogenic	 role	of	mutations	 in	 this	gene	
identified	in	epileptic	individuals.		
	
Quinidine	 is	 predominantly	 used	 as	 an	 antiarrhythmic	 agent	 (class	 IA)	 and	 is	
approved	 by	 the	US	 Food	 and	 Drug	 Administration	 for	 that	 indication,	 as	well	 as	 for	
treatment	 of	 Plasmodium	 falciparum	 malaria.	 Quinidine	 is	 well	 absorbed	 in	 the	
gastrointestinal	 tract	 and	 is	 rapidly	 and	 widely	 distributed	 throughout	 the	 body,	
although	 its	 central	 nervous	 system	 penetration	 is	 relatively	 poor.	 Quinidine	 is	




prolongation	 is	 a	 common	 adverse	 effect.	 Therefore,	 quinidine	 should	 be	 used	 with	
caution	 in	combination	with	other	medications	 that	may	prolong	 the	QT	 interval,	and	
EKG	monitoring	should	be	considered	[Kusuhara	et	al.,	1997].	Given	that	the	functional	
characterization	 of	 all	 the	 KCNT1	 and	 KCNT2	 mutations	 herein	 investigated	 are	
associated	 to	 a	 significant	 increase	 in	 channel	 function,	 we	 have	 explored	 the	
hypothesis	that	KCNT	channels	blockers	could	be	useful	to	counteract	these	mutation-
induced	 functional	 effects	 [Yang	 et	 al.,	 2006].	 Notably,	 our	 results	 revealed	 that	 all	
mutant	KCNT1	and	KCNT2	channels	herein	investigated	showed	a	significant	increase	in	
current	blockade	by	quinidine	and/or	bepridil	when	compared	 to	corresponding	wild-
type	 channels.	 This	 increased	 sensitivity	 of	 mutant	 channels	 could	 be	 due	 to	 the	
mutation-induced	 negative	 shifts	 of	 the	 activation	 gating	 observed	 in	 all	 KCNT1	 or	
KCNT2	mutant	channels,	 leading	to	an	increased	availability	of	mutant	channels	 in	the	
open	configuration,	that	would	favor	the	interaction	of	bepridil	and	quinidine	with	this	
state	 of	 KCNT	 channels:	 these	 results	 carry	 novel	 pharmacogenomics	 implications	 for	
the	treatment	of	epileptic	encephalopathies	such	as	MMPSI.		
The	 first	 report	 repurposing	 the	use	of	quinidine	 in	a	3	year-old	girl	with	MMPSI	who	
had	5	 to	 20	 seizures	 per	 day,	 described	 a	marked	 improvement	 in	 seizure	 control	 so	
that	 she	was	 only	 experiencing	 seizures	 at	 the	 time	 of	 homeostatic	 stress,	 e.g.,	 with	
intercurrent	 infection	on	 treatment	 [Bearden	et	al.,	2014].	Similarly,	Milligan	and	coll.	
(2014)	 found	 a	 significant	 effect	 of	 quinidine	 in	 a	 patient	 with	MMPSI,	 but	 not	 in	 a	
second	patient	with	ADNFLE.	
Efficacy	 of	 quinidine	 in	 MMPSI	 patients	 may	 depend	 on	 the	 underlying	 genetic	
mutation,	as	well	as	the	age	of	patients	and	the	epileptic	phenotype,	although	a	clear	
genotype-phenotype	correlation	remains	to	be	clarified	[Mikati	et	al.,	2015].			
Furthermore,	 the	 therapeutic	 range	 for	 quinidine	 as	 an	 anticonvulsant	 in	 KCNT1-	 or	
KCNT2-realted	epilepsies	has	yet	to	be	established	and	quinidine	use	in	MMPSI	patients	
in	 the	 literature	 suggests	 the	 need	 for	 caution	 in	 introducing	 presumed	 precision	
therapies	for	the	severe	genetic	epilepsies.	
However,	 quinidine	 is	 a	 weak	 antagonist	 of	 KCNT	 channels	 and	 has	 a	 relatively	 poor	
blood-brain	 barrier	 penetration	 and	 hence	 may	 not	 have	 achieved	 sufficient	
	 80	
concentrations	 in	 the	 brain	 to	 normalize	 pathological	 KCNT	 conductance.	 Notably,	
preliminary	 results	 on	 quinidine	 treatment	 of	 the	 patient	 carrying	 KCNT2-R190H	
mutation	 suggest	 an	 improvement	 of	 the	 clinical	 parameters,	 especially	 in	 terms	 of	
seizure	 frequency,	 although	 several	 clinical	 implications	 may	 be	 considered.	 In	 this	
patient,	quinidine	serum	levels	were	found	to	be	0.7	mg/l,	a	value	much	lower	than	the	
therapeutic	 plasma	 range	 (2–5	 mg/l)	 indicated	 for	 its	 use	 as	 an	 antiarrhythmic	
[Routledge	 and	 Hutchings,	 2013].	 Given	 the	 hypothesized	 developmental function	 of	
KCNT1	 channels	 via	 interaction	 with	 FMRP,	 it	 is	 possible	 that	 there	 was	 irreversible	





the	 first	 randomized	 trial	of	oral	 administration	of	quinidine	 (300	mg/d)	 to	6	patients	





Further	 studies	 are	 needed	 to	 definitively	 demonstrate	 the	 efficacy	 of	 quinidine,	





















5. Bearden	D,	Strong	A,	Ehnot	 J,	DiGiovine	M,	Dlugos	D,	Goldberg	EM	 (2014).	Targeted	
treatment	of	migrating	partial	seizures	of	infancy	with	quinidine.	Annals	of	Neurology.	
76,	457–461.	
6. Berg	 AT,	 Berkovic	 SF,	 Brodie	MJ,	 Buchhalter	 J,	 Cross	 JH,	 van	 Emde	 Boas	W,	 Engel	 J,	
French	 J,	Glauser	TA,	Mathern	GW,	Moshé	SL,	Nordli	D,	Plouin	P,	 Scheffer	 IE	 (2010).	
Revised	terminology	and	concepts	for	organization	of	seizures	and	epilepsies:	report	of	










is	 an	 opener	 of	 the	 sodium-activated	 potassium	 channel	 slack	 (Slo2.2).	 Journal	 of	
Pharmacology	and	Experimental	Therapeutics	340,	706-715.	
11. Brown	M,	 Kronengold	 J,	Gazula	V,	 Spilianakis	 C,	 Flavell	 R,	 von	Hehn	C	 et	 al.,	 (2008).	






13. Carranza	 Rojo	 D,	Hamiwka	 L,	McMahon	 JM,	Dibbens	 LM,	Arsov	 T,	Suls	 A,	Stödberg	
T,	Kelley	 K,	Wirrell	 E,	Appleton	 B,	Mackay	 M,	Freeman	 JL,	Yendle	 SC,	Berkovic	
SF,	Bienvenu	T,	De	 Jonghe	P,	Thorburn	DR,	Mulley	 JC,	Mefford	HC,	Scheffer	 IE	 (2011).	






15. Choi	M,	Scholl	UI,	 Ji	W,	Liu	T,	Tikhonova	 IR,	Zumbo	P,	Nayir	A,	Bakkaloğlu	A,	Ozen	S,	
Sanjad	 S,	Nelson-Williams	C,	 Farhi	A,	Mane	S,	 Lifton	RP	 (2009).	Genetic	diagnosis	by	
whole	 exome	 capture	 and	 massively	 parallel	 DNA	 sequencing.	 Proceedings	 of	 the	
National	Academy	of	Science	106(45):19096-101.	
16. Chopra	 R,	 Isom	 LL	 (2014).	 Untangling	 the	 dravet	 syndrome	 seizure	 network:	 the	
changing	face	of	a	rare	genetic	epilepsy.	Epilepsy	Currents	14(2):86-9.	
17. Claes	L,	Del-Favero	J,	Ceulemans	B,	Lagae	L,	Van	Broeckhoven	C,	De	Jonghe	P	(2001).	
De	 novo	 mutations	 in	 the	 sodium-channel	 gene	 SCN1A	 cause	 severe	 myoclonic	
epilepsy	of	infancy.	American	Journal	of	Human	Genetics	68(6):1327-32.	




20. Deciphering	 Developmental	 Disorders	 S.	 Prelevance	 and	 architecture	 of	 de	 novo	
mutations	in	developmental	disorders	(2017).	Nature	542(7642):433-8.	





23. Dulac	O,	 (2005).	Malignant	migrating	partial	seizure	 in	 infancy.	 In	Roger	J,	Bureau	M,	
Dravet	 Ch,	 Genton	 P,	 Tassinari	 CA,	 Wolf	 O	 (Eds)	 Epileptic	 syndromes	 in	 infancy,	
childhood	 and	 adolescence,	 4th	 edn.	 John	 Libbey	 Eurotext	 Ltd,	 Montrouge,	 France,	
pp73-76.	
24. Evely	KM,	Pryce	 KD,	Bhattacharjee	 A	 (2017).	 The	 Phe932Ile	 mutation	
in	KCNT1	channels	 associated	 with	 severe	 epilepsy,	 delayed	 myelination	 and	
leukoencephalopathy	 produces	 a	 loss-of-function	 channel	 phenotype.	 Neuroscience	
20;	351:65-70.	
25. Fisher	 RS,	van	 Emde	 Boas	 W,	Blume	 W,	Elger	 C,	Genton	 P,	Lee	 P,	Engel	 J	 Jr	 (2005).	
Epileptic	 seizures	 and	 epilepsy:	 definitions	 proposed	 by	 the	 International	 League	




27. Gorman	 AL	 and	 Thomas	 MV	 (1980).	 Potassium	 conductance	 and	 internal	 calcium	
accumulation	in	a	molluscan	neurone.	Journal	of	Physiology	308,	287-313.	
28. Gururaj	 S,	Palmer	 EE,	Sheehan	 GD,	Kandula	 T,	Macintosh	 R,	Ying	 K,	Morris	 P,	Tao	
J,	Dias	KR,	Zhu	Y,	Dinger	ME,	Cowley	MJ,	Kirk	EP,	Roscioli	T,	Sachdev	R,	Duffey	ME,	Bye	
A,	Bhattacharjee	 A	 (2017).	 A	 de	 novo	 mutation	 in	 the	 Sodium-Activeted	 Potassium	
Channel	KCNT2	aters	ion	selectivity	and	cause	Epileptic	Encephalopathy.	Cell	Reports.	
21(4):926-933	
29. Gustaffsson	 B	 and	 Wingstrom	 H	 (1983).	 Hyperpolarization	 following	 long-lasting	
tetanic	activation	of	hippocampal	pyramidal	cells.	Brain	Research	275,	159-169.	




32. Heilbig	 I,	 von	 Deimling	 M,	 Marsh	 ED	 (2017)	 Epileptic	 Encephalopathies	 as	
neurodegenerative	disorders.	Advances	in	Neurobiology	15:295-315.		
	 83	
33. Helbig	KL,	Farwell	 Hagman	 KD,	Shinde	 DN,	Mroske	 C,	Powis	 Z,	Li	 S,	Tang	 S,	Helbig	I	
(2016).	 Diagnostic	exome	 sequencing	provides	 a	 molecular	diagnosis	for	 a	 significant	
proportion	of	patients	with	epilepsy.	Genetics	in	Medicine	18(9):898-90.	
34. Heron	 SE,	 Smith	 KR,	 Bahlo	 M	 et	 al.,	 (2012).	 Missense	 mutations	 in	 the	 sodium-
activated	potassium	channel	gene	KCNT1	cause	severe	autosomal	dominant	nocturnal	
frontal	lobe	epilepsy.	Nature	Genetics	44(11):1188-90.	




37. Hmaimess	 G,	Kadhim	 H,	Nassogne	 MC,	Bonnier	 C,	van	 Rijckevorsel	 K	 (2006).	
Levetiracetam	 in	 a	 neonate	 with	 malignant	 migrating	 partial	 seizures.	 Pediatric	
Neurology	34(1):55-9.	
38. Ishii	A,	Shioda	M,	Okumura	A,	Kidokoro	H,	Sakauchi	M,	Shimada	S,	Shimizu	T,	Osawa	
M,	Hirose	S,	Yamamoto	T	 (2013).	A	 recurrent	KCNT1	mutation	 in	 two	sporadic	cases	
with	malignant	migrating	partial	seizure	of	infancy.	Gene	531,	467-471.	
39. Jacobson	MP,	 Pincus	 DL,	 Rapp	 CS	 et	 al.,	 (2004).	 A	 hierarchical	 approach	 to	 all-atom	
protein	loop	prediction.	Proteins	55(2):351-67.	
40. Joiner	 WJ,	 Tang	 MD,	 Wang	 LY,	 Dworetzky	 SI,	 Boissard	 CG,	 Gan	 L,	 Gribkoff	 VK,	
Kaczmarek	 LK	 (1998).	 Formation	 of	 intermediate	 –conductance	 calcium-activated	








43. Kameyama	 M	 et	 al.,	 (1984).	 Intracellular	 Na+	 activates	 K+	 channels	 in	 mammalian	
cardiac	cells.	Nature	309,	354-356.	
44. Kim	 G	 and	 Kaczmarek	 L	 (2014).	 Emerging	 role	 of	 the	 KCNT1	 Slack	 channel	 in	
intellectual	disability.	Frontiers	in	Cellular	Neuroscience	28,	8:209.	
45. Kim	 GE,	 Kronengold	 J,	 Barcia	 G,	 Imran	 HQ,	 Martin	 HC,	 Blair	 E,	 Taylor	 JC,	 Dulac	 O,	
Colleaux	L,	Nabbout,	Kaczmarek	KL	(2014).	Human	Slack	potassium	channel	mutations	
increase	 positive	 cooperativity	 between	 individual	 channels.	Cell	 reports.	
2014;9(5):1661-1672.		
46. Kurahashi	 H	 and	 Hirose	 S	 In	 Adam	 MP,	Ardinger	 HH,	Pagon	 RA,	Wallace	 SE,	Bean	
LJH,	Mefford	 HC,	Stephens	 K,	Amemiya	 A,	Ledbetter	 N,	 editors	 (2015).	 Autosomal	
Dominant	Nocturnal	Frontal	Lobe	Epilepsy.	GeneReviews®		
47. Kusuhara	H,	Suzuki	H,	Terasaki	T,	et	al.	 (1997).	P-glycoprotein	mediates	 the	efflux	of	
quinidine	 across	 the	 blood-brain	 barrier.	 The	 Journal	 of	 pharmacology	 and	
experimental	therapeutics	283:574–580.	
48. Lee	 H,	 Lin	 MC,	 Kornblum	 HI,	 Papazian	 DM,	 Nelson	 SF,	 (2014).	 Exome	 sequencing	
identifies	de	novo	gain	of	function	missense	mutation	in	KCND2	in	identical	twins	with	
autism	 and	 seizures	 that	 slows	 potassium	 channel	 inactivation.	 Human	 Molecular	
Genetics	23,	3481–3489.	
49. Li	Y,	Sato	T,	Arita	M	(1999)	Bepridil	blunts	the	shortening	of	action	potential	duration	





the	 phenotypic	 spectrum	 and	 functional	 effects.	 Journal	 of	 Medical	 Genetics	
53(4):217-25.	
51. Martin	 HC,	 Kim	 GE,	 Pagnamenta	 AT,	 Murakami	 Y,	 Carvill	 GL,	 Meyer	 E,	 Copley	 RR,	
Rimmer	A,	Barcia	G,	Fleming	MR,	Kronengold	J,	Brown	MR,	Hudspith	KA,	et	al.,	(2014).	
Clinical	whole-exome	 sequencing	 in	 severe	 early-onset	 epileptic	 epilepsy	 reveal	 new	
genes	and	improves	molecular	diagnosis.	Human	Molecular	Genetics	23,	3200-3211.	
52. Martinez-Espinosa	PL,	Wu	J,	Yang	C,	Gonzalez-Perez	V,	Zhou	H,	Liang	H,	Xia	XM,	Lingle	
CJ	 (2015).	 Knockout	 of	 Slo2.2	 enhances	 itch,	 abolishes	 KNa	 current,	 and	 increases	
action	potential	firing	frequency	in	DRG	neurons.	Elife	11,4.	
53. Mc	Tague	A,	Appleton	R,	Avula	S,	Cross	JH,	King	M	D,	Jacques	T	S,	Bhate	S,	Cronin	A,	








in	 the	voltage	 sensor	of	Kv7.2	and	Kv7.3	potassium	channel	 subunits.	The	 Journal	of	
Neuroscience	35:	3782–3793.	
56. Mikati	 MA,	Jiang	 YH,	Carboni	 M,	Shashi	 V,	Petrovski	 S,	Spillmann	 R,	Milligan	 CJ,	Li	




F,	 Zara	 F,	 Chabrol	 B,	 Villard	 L,	 Fassio	 A	 (2013).	 Novel	 compound	 heterozygous	
mutations	 in	 TBC1D24	 cause	 familial	malignant	migrating	 partial	 seizures	 of	 infancy.	
Human	Mutation	34(6):869-72.	
58. Milligan	CJ,	Li	M,	Gazina	EV,	Heron	SE,	Nair	U,	Trager	C,	Reid	CA,	Vankat	A,	Younkin	DP,	
Dlugos	DJ,	 Petrovski	 S,	Goldstein	DB,	Dibbens	 LM,	 Scheffer	 IE,	 Berkovic	 SF,	 Petrou	 S	
(2014).	 KCNT1	 gain	 of	 function	 in	 2	 epilepsy	 phenotypes	 is	 reversed	 by	 quinidine.	
Annals	of	Neurology	75,	581-590.	
59. Mitani	 A	 and	 Shattock	 MJ	 (1992).	 Role	 of	 Na+-activated	 K+	 channels,	 Na+	 -K+	 -Cl-	






61. Møller	 RS,	Heron	 SE,	Larsen	 LH,	Lim	 CX,	Ricos	 MG,	Bayly	 MA,	van	 Kempen	
MJ,	Klinkenberg	 S,	Andrews	 I,	Kelley	 K,	Ronen	 GM,	Callen	 D,	McMahon	 JM,	Yendle	
SC,	Carvill	GL,	Mefford	HC,	Nabbout	R,	Poduri	A,	Striano	P,	Baglietto	MG,	Zara	F,	Smith	
NJ,	Pridmore	 C,	Gardella	 E,	Nikanorova	 M,	Dahl	 HA,	Gellert	 P,	Scheffer	 IE,	Gunning	
B,	Kragh-Olsen	B,	Dibbens	 LM	 (2015).	Mutations	 in	 KCNT1	 cause	 a	 spectrum	of	 focal	
epilepsy.	Epilepsia	56(9).	
62. Mori	K,	Saito	T,	Masuda	Y,	Nakaya	H	(1998).	Effects	of	class	III	antiarrhythmic	drug	on	
the	Na+-activated	 K+	 channels	 in	 guinea-pig	 ventricular	 cells.	Naunyn-Schmiedeberg’s	
Archives	of	Pharmacology	358,6	641-648.	
63. Mullen	 SA,	Carney	 PW,	Roten	 A,	Ching	 M,	Lightfoot	 PA,	Churilov	 L,	Nair	 U,	Li	
M,	Berkovic	 SF,	Petrou	 S,	Scheffer	 IE	 (2017).	 Precision	 therapy	 for	 epilepsy	 due	 to	
	 85	
KCNT1	 mutations:	 a	 randomized	 trial	 of	 oral	 quinidine.	 Neurology	 [Epub	 ahead	 of	
print].	
64. Nakamura	K,	Kato	M,	Osaka	H,	 Yamashita	 S,	Nakagawa	E,	Haginoya	K,	 et	 al.,	 (2013).	
Clinical	 spectrum	 of	 SCN2A	mutations	 expanding	 to	 Ohtahara	 syndrome.	Neurology	
81,	992-998.	
65. Nieh	 SE	 and	 Sherr	 EH	 (2014).	 Epileptic	 Encephalopathies:	 New	 Genes	 and	 New	
Pathways.	Neurotherapeutics	11(4):	796–806.	
66. Ohtahara	 S,	 Ishida	 T,	 Oka	 E,	 Yamatogy	 Y,	 Inoue	 H	 (1976).	 On	 the	 specific	 age-





















74. Scheffer	 IE,	Berkovic	S,	Capovilla	G	et	al.,	 (2017).	 ILAE	classification	of	 the	epilepsies:	
Position	 paper	 of	 the	 ILAE	 Commission	 for	 Classification	 and	 Terminology.	 Epilepsia	
58(4):512-521.	
75. Schwindt	PC,	Spain	WJ,	Foehring	RC,	Chubb	MC,	Crill	WE	(1988a).	Slow	conductances	
in	 neurons	 from	 cat	 sensorimotor	 cortex	 in	 vitro	 and	 their	 role	 in	 slow	 excitability	
changes.	Journal	of	Neurophysiology	59,	450-467.	
76. Schwindt	 PC,	 Spain	 WJ,	 Foehring	 RC,	 Stafstrom	 CE,	 Chubb	 MC,	 Crill	 WE	 (1988b).	
Multiple	 potassium	 conductances	 and	 their	 functions	 in	 neurons	 from	 cat	
sensorimotor	cortex	in	vitro.	Journal	of	Neurophysiology	59,	424-449.	
77. Sicca	F,	Imbrici	P,	D'Adamo	MC,	Moro	F,	Bonatti	F,	Brovedani	P,	Grottesi	A,	Guerrini	R,	
Masi	 G,	 Santorelli	 FM,	 Pessia	 M,	 (2011).	 Autism	 with	 seizures	 and	 intellectual	
disability:	 possible	 causative	 role	 of	 gain-of-function	 of	 the	 inwardly-rectifying	 K+	
channel	Kir4.1.	Neurobiology	Disease	43,	239–247.	
78. Singh	NA,	Charlier	 C,	Stauffer	 D,	DuPont	 BR,	Leach	 RJ,	Melis	 R,	Ronen	 GM,	Bjerre	
I,	Quattlebaum	T,	Murphy	 JV,	McHarg	ML,	Gagnon	D,	Rosales	 TO,	Peiffer	A,	Anderson	
VE,	Leppert	 M	 (1998).	 A	 novel	 potassium	 channel	 gene,	KCNQ2,	 is	 mutated	 in	 an	
inherited	epilepsy	of	newborns.	Nature	Genetics	18(1):25-9.	
79. Steinlein	 OK,	Mulley	 JC,	Propping	 P,	Wallace	 RH,	Phillips	 HA,	Sutherland	 GR,	Scheffer	





Yamakawa	 K	 (2002).	 Frequent	 mutations	 of	 SCN1A	 in	 severe	 myoclonic	 epilepsy	 in	
infancy.	Neurology	58:1122-1124.	
81. Tamsett	TJ,	Picchione	KE	and	Bhattacharjee	A	 (2009).	NAD+	activates	KNa	 channels	 in	
dorsal	root	ganglion	neurons.	Journal	of	Neuroscience	29,	5127-5134.	
82. Tejada	 MD,	 Jensen	 LJ,	 Klaerke	 DA	 (2012).	 PIP(2)	 modulation	 of	 Slick	 and	 Slack	 K+	
channels.	Biochemical	and	Biophysical	Research	Communications	424,	208-213.	




85. Wallen	 P,	 Robertson	 B,	 Cangiano	 L,	 Low	 P,	 Bhattacharjee	 A,	 Kaczmarek	 LK	 et	 al.,	
(2007).	 Sodium-dependent	 potassium	 channels	 of	 a	 Slack-like	 subtype	 contribute	 to	
the	slow	afterhyperpolarization	 in	 lamprey	spinal	neurons.	Journal	of	Physiology	585,	
75-90.	
86. Watanabe	 T,	 Sadamoto	 H,	 Aonuma	 H.	 (2013).	 Molecular	 basis	 of	 the	 dopaminergic	
system	in	the	cricket	Gryllus	bimaculatus.	Invertebrate	Neuroscience.	13(2):107-23. 	
87. Yang	 B,	 Desai	 R,	 Kaczmarek	 LK	 (2007).	 Slack	 and	 Slick	 K(Na)	 channels	 regulate	 the	
accuracy	of	timing	of	auditory	neurons.	Journal	of	Neuroscience	27(10):2617-27.	
88. Yang	B,	Gribkoff	VK,	Pan	J,	Damagnez	SI,	Boissard	CG,	Bhattacharjee	A,	Yan	Y,	Sigworth	






90. Yuan	 A,	 Dourado	 M,	 Butler	 A,	 Walton	 N,	 Wei	 A	 and	 Salkoff	 L	 (2000).	 SLO-2,	 a	 K+	
channel	with	an	unusual	Cl-	dependence.	Nature	Neuroscience	3,	771-779.	
91. Yuan	 A,	 Santi	 C,	 Wei	 A	 et	 al.,	 (2003).	 The	 sodium-activated	 potassium	 channel	 is	
encoded	by	a	member	of	the	Slo	gene	family.	Neuron	37(5):765-773.	
92. Zhang	 L,	 Sukhareva	M,	 Barker	 JL	 et	 al.,	 (2005).	 Direct	 binding	 of	 estradiol	 enhances	





















Thanks	 to	Dr.	 Paolo	 Ambrosino	 and	 Dr.	 Ilaria	 Mosca	 for	 their	 hard	 work	 done	 for		
electrophysiological	experiments.	
Thanks	 to	 all	 my	 collegues	Michela	 De	 Maria,	 Ilaria	 Mosca,	 Alessandro	 Medoro,	
Donatella	Mignogna	for	their	friendship	and	for	sharing	every	moments	in	lab.	
Thanks	 to	Fabrizio	and	my	family	 for	 their	 important	support	during	 these	years,	 for	
their	presence…for	their	existence.	
 
